false--12-31FY201810-K000161385965531659YesfalseLarge Accelerated FilerPRA Health Sciences, Inc.falsefalseNoYesP6MP1DP12MP0Y00.0110000000001000000000636239506539452663623950653945260.0125P5YP1Y1000001000000000046700002303000269900016490006220009600010070000.011000000001000000000000P7YP7YP3YP5YP1YP3YP1YP2Y83.252.9475.8116.42116.1111.7382.9975.37 0001613859 2018-01-01 2018-12-31 0001613859 2018-06-30 0001613859 2019-02-22 0001613859 2018-12-31 0001613859 2017-12-31 0001613859 2017-01-01 2017-12-31 0001613859 2016-01-01 2016-12-31 0001613859 prah:DirectCostsMember 2017-01-01 2017-12-31 0001613859 prah:ReimbursableInvestigatorFeesMember 2018-01-01 2018-12-31 0001613859 prah:DirectCostsMember 2018-01-01 2018-12-31 0001613859 prah:ReimbursableOutOfPocketCostsMember 2017-01-01 2017-12-31 0001613859 prah:ReimbursableOutOfPocketCostsMember 2018-01-01 2018-12-31 0001613859 prah:DirectCostsMember 2016-01-01 2016-12-31 0001613859 prah:ReimbursableInvestigatorFeesMember 2016-01-01 2016-12-31 0001613859 prah:ReimbursableOutOfPocketCostsMember 2016-01-01 2016-12-31 0001613859 prah:ReimbursableInvestigatorFeesMember 2017-01-01 2017-12-31 0001613859 2015-12-31 0001613859 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001613859 us-gaap:CommonStockMember 2015-12-31 0001613859 us-gaap:RetainedEarningsMember 2016-12-31 0001613859 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001613859 us-gaap:CommonStockMember 2018-12-31 0001613859 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0001613859 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001613859 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001613859 us-gaap:RetainedEarningsMember 2018-12-31 0001613859 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001613859 2016-12-31 0001613859 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001613859 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001613859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001613859 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001613859 us-gaap:RetainedEarningsMember 2015-12-31 0001613859 us-gaap:RetainedEarningsMember 2017-12-31 0001613859 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-12-31 0001613859 us-gaap:CommonStockMember 2017-12-31 0001613859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0001613859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0001613859 us-gaap:CommonStockMember 2018-01-01 0001613859 us-gaap:RetainedEarningsMember 2018-01-01 0001613859 us-gaap:NoncontrollingInterestMember 2018-01-01 0001613859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001613859 2018-01-01 0001613859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001613859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001613859 us-gaap:NoncontrollingInterestMember 2016-12-31 0001613859 us-gaap:CommonStockMember 2016-12-31 0001613859 us-gaap:NoncontrollingInterestMember 2015-12-31 0001613859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001613859 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0001613859 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001613859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001613859 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001613859 us-gaap:NoncontrollingInterestMember 2018-12-31 0001613859 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 0001613859 us-gaap:NoncontrollingInterestMember 2017-12-31 0001613859 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001613859 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001613859 prah:SecondaryPublicOfferingMember 2017-01-01 2017-12-31 0001613859 prah:KohlbergKravisRobertsCoLpAndCertainExecutiveOfficersMember prah:SecondaryPublicOfferingMember 2017-01-01 2017-12-31 0001613859 prah:KohlbergKravisRobertsCoLpAndCertainExecutiveOfficersMember prah:SecondaryPublicOfferingMember 2018-01-01 2018-12-31 0001613859 prah:KohlbergKravisRobertsCoLPMember 2018-01-01 2018-12-31 0001613859 prah:SecondaryPublicOfferingMember 2018-01-01 2018-12-31 0001613859 prah:SecondaryPublicOfferingMember 2016-01-01 2016-12-31 0001613859 prah:KohlbergKravisRobertsCoLpAndCertainExecutiveOfficersMember prah:SecondaryPublicOfferingMember 2016-01-01 2016-12-31 0001613859 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputPriceVolatilityMember 2018-12-31 0001613859 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 0001613859 us-gaap:AccountingStandardsUpdate201609Member us-gaap:RetainedEarningsMember 2017-12-31 0001613859 2019-01-01 2018-12-31 0001613859 srt:MinimumMember 2018-01-01 2018-12-31 0001613859 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2018-12-31 0001613859 prah:EDSPRandSSMember prah:ClinicalResearchMember 2018-12-31 0001613859 prah:AccountingStandardsUpdate201609ExcessTaxBenefitsComponentMember 2017-12-31 0001613859 us-gaap:ServiceMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2016-01-01 2016-12-31 0001613859 us-gaap:FairValueInputsLevel3Member us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-01-01 2018-12-31 0001613859 us-gaap:AccountingStandardsUpdate201609Member 2017-12-31 0001613859 us-gaap:ServiceMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-01-01 2017-12-31 0001613859 prah:ReimbursementMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-01-01 2017-12-31 0001613859 srt:MaximumMember 2018-01-01 2018-12-31 0001613859 prah:ServiceInKindMember prah:DataSolutionsMember 2018-01-01 2018-12-31 0001613859 prah:DataSolutionsMember 2018-12-31 0001613859 us-gaap:FairValueInputsLevel3Member prah:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-01-01 2018-12-31 0001613859 srt:MaximumMember 2019-01-01 2018-12-31 0001613859 prah:ReimbursableInvestigatorFeesMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-01-01 2017-12-31 0001613859 prah:ServiceInKindMember prah:DataSolutionsMember 2017-01-01 2017-12-31 0001613859 us-gaap:FairValueInputsLevel3Member us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 prah:ReimbursementMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2016-01-01 2016-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember us-gaap:FairValueInputsLevel3Member prah:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-01-01 2017-12-31 0001613859 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember 2018-12-31 0001613859 us-gaap:SecuredDebtMember 2018-05-31 0001613859 prah:ReimbursableInvestigatorFeesMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2016-01-01 2016-12-31 0001613859 prah:DirectCostsMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001613859 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001613859 prah:ReimbursableOutOfPocketCostsMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001613859 prah:AccountingStandardsUpdate201409ImpactFromAdoptionOfASC606Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001613859 prah:ReimbursableInvestigatorFeesMember prah:AccountingStandardsUpdate201409ImpactFromAdoptionOfASC606Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001613859 prah:DirectCostsMember prah:AccountingStandardsUpdate201409ImpactFromAdoptionOfASC606Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001613859 prah:ReimbursementMember prah:AccountingStandardsUpdate201409ReclassificationFromAdoptionOfASC606Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001613859 prah:ReimbursableOutOfPocketCostsMember prah:AccountingStandardsUpdate201409ImpactFromAdoptionOfASC606Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001613859 us-gaap:ServiceMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001613859 prah:AccountingStandardsUpdate201409ReclassificationFromAdoptionOfASC606Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001613859 prah:ReimbursableInvestigatorFeesMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001613859 prah:ReimbursementMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001613859 us-gaap:ServiceMember prah:AccountingStandardsUpdate201409ReclassificationFromAdoptionOfASC606Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001613859 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001613859 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001613859 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0001613859 prah:NextrialsIncMember us-gaap:FairValueInputsLevel3Member prah:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-01-01 2017-12-31 0001613859 prah:ParallelSixMember us-gaap:FairValueInputsLevel3Member prah:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-01-01 2017-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-01-01 2017-12-31 0001613859 us-gaap:FairValueInputsLevel3Member prah:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-01-01 2017-12-31 0001613859 prah:ParallelSixMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-01-01 2017-12-31 0001613859 us-gaap:FairValueInputsLevel3Member prah:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 us-gaap:FairValueInputsLevel3Member us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-01-01 2017-12-31 0001613859 us-gaap:FairValueInputsLevel3Member us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001613859 us-gaap:FairValueInputsLevel3Member prah:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001613859 prah:NextrialsIncMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-01-01 2017-12-31 0001613859 us-gaap:FairValueInputsLevel3Member prah:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001613859 us-gaap:FairValueInputsLevel3Member us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001613859 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 us-gaap:FairValueInputsLevel2Member prah:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 prah:MarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 prah:MarketableSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 prah:MarketableSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 us-gaap:FairValueInputsLevel1Member prah:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 prah:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 us-gaap:FairValueInputsLevel3Member prah:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 prah:MarketableSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 prah:CustomerAMember us-gaap:SalesRevenueServicesNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001613859 prah:CustomerAMember us-gaap:SalesRevenueServicesNetMember us-gaap:CustomerConcentrationRiskMember 2016-01-01 2016-12-31 0001613859 prah:CustomerBMember us-gaap:SalesRevenueServicesNetMember us-gaap:CustomerConcentrationRiskMember 2016-01-01 2016-12-31 0001613859 prah:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001613859 prah:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001613859 prah:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001613859 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001613859 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001613859 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001613859 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001613859 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001613859 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001613859 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001613859 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001613859 srt:MinimumMember 2019-01-01 2018-12-31 0001613859 srt:MaximumMember prah:FurnitureAndEquipmentMember 2018-01-01 2018-12-31 0001613859 srt:MinimumMember prah:FurnitureAndEquipmentMember 2018-01-01 2018-12-31 0001613859 srt:MaximumMember prah:ComputerEquipmentAndSoftwareMember 2018-01-01 2018-12-31 0001613859 srt:MinimumMember prah:ComputerEquipmentAndSoftwareMember 2018-01-01 2018-12-31 0001613859 prah:A2praCorporationJointVentureMember 2018-12-31 0001613859 prah:A2praCorporationJointVentureMember us-gaap:ScenarioForecastMember 2019-01-01 2019-03-31 0001613859 prah:PRAWuXiJointVentureMember 2016-05-06 2016-05-06 0001613859 prah:WuxipraJointVentureHongKongMember 2016-05-06 2016-05-06 0001613859 prah:A2praCorporationJointVentureMember 2017-12-31 0001613859 prah:PRAWuXiJointVentureMember 2016-05-06 0001613859 prah:A2HealthcareCorporationMember prah:A2praCorporationJointVentureMember 2018-12-31 0001613859 prah:A2praCorporationJointVentureMember 2018-01-01 2018-12-31 0001613859 prah:A2praCorporationJointVentureMember 2016-01-01 2016-12-31 0001613859 prah:A2praCorporationJointVentureMember 2017-01-01 2017-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember 2017-01-01 2017-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember 2018-01-01 2018-12-31 0001613859 prah:ParallelSixMember 2017-05-10 0001613859 prah:ParallelSixMember us-gaap:ComputerSoftwareIntangibleAssetMember 2017-05-10 2017-05-10 0001613859 prah:ParallelSixMember us-gaap:OtherIntangibleAssetsMember 2017-05-10 2017-05-10 0001613859 prah:ParallelSixMember us-gaap:ComputerSoftwareIntangibleAssetMember 2017-05-10 0001613859 prah:ParallelSixMember us-gaap:OtherIntangibleAssetsMember 2017-05-10 0001613859 prah:TakedaPraDevelopmentCenterKkMember 2017-06-01 0001613859 prah:SymphonyHealthSolutionsCorporationMember us-gaap:AcquisitionRelatedCostsMember 2017-12-31 0001613859 prah:TakedaPraDevelopmentCenterKkMember 2017-06-01 2017-06-01 0001613859 prah:NextrialsIncMember prah:ContingentEarnOutPaymentsMilestoneOneMember 2016-03-18 0001613859 prah:TakedaPraDevelopmentCenterKkMember 2017-01-01 2017-12-31 0001613859 prah:NextrialsIncMember prah:ContingentEarnOutPaymentsMember 2016-03-18 2016-03-18 0001613859 prah:ParallelSixMember prah:ContingentEarnOutPaymentsSalesTargetsMember 2017-05-10 2017-05-10 0001613859 prah:NextrialsIncMember prah:ContingentEarnOutPaymentsMember 2017-10-01 2017-12-31 0001613859 prah:ParallelSixMember 2018-01-01 2018-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember 2017-09-06 0001613859 prah:SymphonyHealthSolutionsCorporationMember us-gaap:AcquisitionRelatedCostsMember 2017-01-01 2017-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember prah:ContingentEarnOutPaymentsMember 2017-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember 2017-09-06 2018-12-31 0001613859 prah:ParallelSixMember us-gaap:FairValueInputsLevel3Member 2017-05-10 0001613859 prah:SymphonyHealthSolutionsCorporationMember 2017-09-06 2017-09-06 0001613859 prah:SymphonyHealthSolutionsCorporationMember prah:ContingentEarnOutPaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-06 0001613859 prah:NextrialsIncMember prah:ContingentEarnOutPaymentsMember 2017-01-01 2017-12-31 0001613859 prah:TakedaPharmaceuticalDataServicesIncMember 2017-06-01 0001613859 prah:SymphonyHealthSolutionsCorporationMember prah:ContingentEarnOutPaymentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001613859 prah:TakedaPharmaceuticalCompanyLtdMember prah:TakedaPraDevelopmentCenterKkMember 2017-06-01 2017-06-01 0001613859 prah:NextrialsIncMember prah:ContingentEarnOutPaymentsMember us-gaap:FairValueInputsLevel3Member 2016-03-18 0001613859 prah:NextrialsIncMember 2016-03-18 0001613859 prah:ParallelSixMember 2017-05-10 2017-05-10 0001613859 prah:SymphonyHealthSolutionsCorporationMember prah:AcquisitionrelatedCostsModificationorExtinguishmentofDebtMember 2017-01-01 2017-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember prah:AcquisitionrelatedCostsTransactionMember 2017-01-01 2017-12-31 0001613859 prah:WuxipraJointVentureHongKongMember 2016-05-06 0001613859 prah:NextrialsIncMember 2016-03-18 2016-03-18 0001613859 prah:ParallelSixMember prah:ContingentEarnOutPaymentsSalesTargetsMember 2017-05-10 0001613859 prah:ParallelSixMember 2017-01-01 2017-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember 2018-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember us-gaap:FairValueInputsLevel3Member 2018-02-28 0001613859 prah:TakedaPharmaceuticalCompanyLtdMember prah:TDCJointVentureMember 2017-06-01 0001613859 prah:SymphonyHealthSolutionsCorporationMember 2017-12-31 0001613859 prah:NextrialsIncMember prah:ContingentEarnOutPaymentsMember 2016-03-18 0001613859 prah:SymphonyHealthSolutionsCorporationMember 2017-10-01 2017-12-31 0001613859 prah:TakedaPharmaceuticalDataServicesIncMember 2017-06-01 2017-06-01 0001613859 prah:NextrialsIncMember prah:ContingentEarnOutPaymentsMilestoneTwoMember 2016-03-18 0001613859 prah:SymphonyHealthSolutionsCorporationMember us-gaap:CustomerRelationshipsMember 2017-09-06 0001613859 prah:SymphonyHealthSolutionsCorporationMember us-gaap:DatabasesMember 2017-09-06 0001613859 prah:SymphonyHealthSolutionsCorporationMember us-gaap:CustomerRelationshipsMember 2017-09-06 2017-09-06 0001613859 prah:SymphonyHealthSolutionsCorporationMember us-gaap:DatabasesMember 2017-09-06 2017-09-06 0001613859 prah:SymphonyHealthSolutionsCorporationMember us-gaap:TradeNamesMember 2017-09-06 2017-09-06 0001613859 prah:SymphonyHealthSolutionsCorporationMember us-gaap:TradeNamesMember 2017-09-06 0001613859 prah:NextrialsIncMember us-gaap:ComputerSoftwareIntangibleAssetMember 2016-03-18 0001613859 prah:NextrialsIncMember us-gaap:ComputerSoftwareIntangibleAssetMember 2016-03-18 2016-03-18 0001613859 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-31 0001613859 prah:ComputerEquipmentAndSoftwareMember 2018-12-31 0001613859 prah:FurnitureAndEquipmentMember 2018-12-31 0001613859 prah:FurnitureAndEquipmentMember 2017-12-31 0001613859 prah:ComputerEquipmentAndSoftwareMember 2017-12-31 0001613859 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001613859 us-gaap:LeaseholdImprovementsMember 2017-12-31 0001613859 prah:TakedaPharmaceuticalDataServicesIncMember prah:DataSolutionsMember 2017-01-01 2017-12-31 0001613859 prah:ParallelSixMember prah:DataSolutionsMember 2018-01-01 2018-12-31 0001613859 prah:ClinicalResearchMember 2018-12-31 0001613859 prah:DataSolutionsMember 2017-12-31 0001613859 prah:TakedaPharmaceuticalDataServicesIncMember prah:ClinicalResearchMember 2017-01-01 2017-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember prah:DataSolutionsMember 2017-01-01 2017-12-31 0001613859 prah:ParallelSixMember prah:DataSolutionsMember 2017-01-01 2017-12-31 0001613859 prah:ClinicalResearchMember 2017-12-31 0001613859 prah:TakedaPharmaceuticalDataServicesIncMember 2017-01-01 2017-12-31 0001613859 prah:ClinicalResearchMember 2016-12-31 0001613859 prah:TDCJointVentureMember prah:DataSolutionsMember 2017-01-01 2017-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember prah:DataSolutionsMember 2018-01-01 2018-12-31 0001613859 prah:DataSolutionsMember 2016-12-31 0001613859 prah:DataSolutionsMember 2018-01-01 2018-12-31 0001613859 prah:TDCJointVentureMember prah:ClinicalResearchMember 2017-01-01 2017-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember prah:ClinicalResearchMember 2018-01-01 2018-12-31 0001613859 prah:ClinicalResearchMember 2018-01-01 2018-12-31 0001613859 prah:ParallelSixMember prah:ClinicalResearchMember 2017-01-01 2017-12-31 0001613859 prah:ClinicalResearchMember 2017-01-01 2017-12-31 0001613859 prah:DataSolutionsMember 2017-01-01 2017-12-31 0001613859 prah:SymphonyHealthSolutionsCorporationMember prah:ClinicalResearchMember 2017-01-01 2017-12-31 0001613859 prah:TDCJointVentureMember 2017-01-01 2017-12-31 0001613859 prah:ParallelSixMember prah:ClinicalResearchMember 2018-01-01 2018-12-31 0001613859 prah:DataSolutionsMember 2018-12-31 0001613859 us-gaap:DatabasesMember 2018-12-31 0001613859 prah:CustomerBacklogMember 2017-12-31 0001613859 us-gaap:CustomerRelationshipsMember 2017-12-31 0001613859 us-gaap:NoncompeteAgreementsMember 2018-12-31 0001613859 us-gaap:DatabasesMember 2017-12-31 0001613859 us-gaap:CustomerRelationshipsMember 2018-12-31 0001613859 us-gaap:TradeNamesMember 2017-12-31 0001613859 us-gaap:TradeNamesMember 2018-12-31 0001613859 us-gaap:NoncompeteAgreementsMember 2017-12-31 0001613859 prah:CustomerBacklogMember 2018-12-31 0001613859 prah:PatientListAndOtherIntangiblesMember 2017-12-31 0001613859 prah:PatientListAndOtherIntangiblesMember 2018-12-31 0001613859 prah:FirstLienTermLoanMember 2017-12-31 0001613859 prah:FirstLienTermLoanMember 2018-12-31 0001613859 us-gaap:SecuredDebtMember 2017-12-31 0001613859 us-gaap:SecuredDebtMember 2018-12-31 0001613859 srt:MaximumMember prah:CreditFacilities2016Member us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-12-31 0001613859 prah:CreditFacilities2016Member us-gaap:RevolvingCreditFacilityMember 2018-01-01 2018-12-31 0001613859 prah:CreditFacilities2016Member prah:FirstLienTermLoanMember 2018-01-01 2018-12-31 0001613859 prah:CreditFacilities2016Member us-gaap:RevolvingCreditFacilityMember 2016-12-06 0001613859 prah:CreditFacilities2016Member 2017-09-06 2017-09-06 0001613859 prah:CreditFacilities2016Member us-gaap:RevolvingCreditFacilityMember 2018-12-31 0001613859 prah:CreditFacilities2016Member 2017-01-01 2017-12-31 0001613859 prah:TermLoansCreditFacilityBorrowingsAndAccountsReceivableFinancingAgreementMember 2018-12-31 0001613859 us-gaap:SecuredDebtMember 2018-05-30 2018-05-30 0001613859 prah:CreditFacilities2013Member prah:FirstLienTermLoanMember 2016-01-01 2016-12-31 0001613859 prah:CreditFacilities2016Member prah:FirstLienTermLoanMember 2016-12-06 0001613859 prah:CreditFacilities2016Member prah:FirstLienTermLoanMember 2017-01-01 2017-12-31 0001613859 prah:CreditFacilities2016Member us-gaap:RevolvingCreditFacilityMember 2017-12-28 0001613859 srt:MinimumMember prah:CreditFacilities2016Member us-gaap:RevolvingCreditFacilityMember 2018-01-01 2018-12-31 0001613859 srt:MinimumMember prah:CreditFacilities2016Member us-gaap:BaseRateMember 2018-01-01 2018-12-31 0001613859 us-gaap:SecuredDebtMember 2018-01-01 2018-12-31 0001613859 prah:TermLoansCreditFacilityBorrowingsAndAccountsReceivableFinancingAgreementMember 2017-12-31 0001613859 prah:CreditFacilities2016Member us-gaap:RevolvingCreditFacilityMember 2017-12-31 0001613859 srt:MaximumMember prah:CreditFacilities2016Member us-gaap:RevolvingCreditFacilityMember 2018-01-01 2018-12-31 0001613859 us-gaap:SecuredDebtMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-12-31 0001613859 prah:CreditFacilities2016Member us-gaap:RevolvingCreditFacilityMember 2016-12-31 0001613859 us-gaap:SecuredDebtMember 2017-01-01 2017-12-31 0001613859 us-gaap:SecuredDebtMember 2018-05-31 2018-05-31 0001613859 srt:MinimumMember prah:CreditFacilities2016Member us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-12-31 0001613859 srt:MaximumMember prah:CreditFacilities2016Member us-gaap:BaseRateMember 2018-01-01 2018-12-31 0001613859 prah:CreditFacilities2016Member 2016-12-06 0001613859 srt:MinimumMember prah:CreditFacilities2016Member us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-12-31 0001613859 us-gaap:SecuredDebtMember 2016-03-31 0001613859 us-gaap:SecuredDebtMember us-gaap:BaseRateMember 2018-01-01 2018-12-31 0001613859 prah:CreditFacilities2016Member us-gaap:RevolvingCreditFacilityMember 2016-12-06 2016-12-06 0001613859 us-gaap:EmployeeStockOptionMember 2018-12-31 0001613859 us-gaap:EmployeeStockOptionMember 2017-12-31 0001613859 us-gaap:EmployeeStockOptionMember prah:ExercisePriceRangeOneMember 2018-12-31 0001613859 us-gaap:EmployeeStockOptionMember prah:ExercisePriceRangeThreeMember 2018-01-01 2018-12-31 0001613859 us-gaap:EmployeeStockOptionMember prah:ExercisePriceRangeOneMember 2018-01-01 2018-12-31 0001613859 us-gaap:EmployeeStockOptionMember prah:ExercisePriceRangeTwoMember 2018-01-01 2018-12-31 0001613859 us-gaap:EmployeeStockOptionMember prah:ExercisePriceRangeTwoMember 2018-12-31 0001613859 us-gaap:EmployeeStockOptionMember prah:ExercisePriceRangeFourMember 2018-12-31 0001613859 us-gaap:EmployeeStockOptionMember prah:ExercisePriceRangeFourMember 2018-01-01 2018-12-31 0001613859 us-gaap:EmployeeStockOptionMember prah:ExercisePriceRangeThreeMember 2018-12-31 0001613859 prah:StockOptionsRestrictedStockAwardsAndRestrictedStockUnitsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0001613859 prah:StockOptionsRestrictedStockAwardsAndRestrictedStockUnitsMember prah:TransactionRelatedCostsMember 2018-01-01 2018-12-31 0001613859 prah:StockOptionsRestrictedStockAwardsAndRestrictedStockUnitsMember prah:DirectCostsMember 2018-01-01 2018-12-31 0001613859 prah:StockOptionsRestrictedStockAwardsAndRestrictedStockUnitsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-12-31 0001613859 prah:StockOptionsRestrictedStockAwardsAndRestrictedStockUnitsMember prah:TransactionRelatedCostsMember 2017-01-01 2017-12-31 0001613859 prah:StockOptionsRestrictedStockAwardsAndRestrictedStockUnitsMember prah:DirectCostsMember 2017-01-01 2017-12-31 0001613859 prah:StockOptionsRestrictedStockAwardsAndRestrictedStockUnitsMember prah:TransactionRelatedCostsMember 2016-01-01 2016-12-31 0001613859 prah:StockOptionsRestrictedStockAwardsAndRestrictedStockUnitsMember 2016-01-01 2016-12-31 0001613859 prah:StockOptionsRestrictedStockAwardsAndRestrictedStockUnitsMember 2018-01-01 2018-12-31 0001613859 prah:StockOptionsRestrictedStockAwardsAndRestrictedStockUnitsMember 2017-01-01 2017-12-31 0001613859 prah:StockOptionsRestrictedStockAwardsAndRestrictedStockUnitsMember prah:DirectCostsMember 2016-01-01 2016-12-31 0001613859 prah:StockOptionsRestrictedStockAwardsAndRestrictedStockUnitsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0001613859 prah:VestingBasedOnMarketConditionsRateOneMember us-gaap:EmployeeStockOptionMember 2013-12-01 2013-12-31 0001613859 prah:VestingBasedOnServiceMember us-gaap:EmployeeStockOptionMember prah:TransactionRelatedCostsMember 2018-01-01 2018-12-31 0001613859 prah:VestingBasedOnMarketConditionsRateOneMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001613859 prah:VestingBasedOnMarketConditionsRateTwoMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001613859 us-gaap:EmployeeStockMember 2018-12-31 0001613859 prah:VestingBasedOnServiceMember us-gaap:EmployeeStockOptionMember prah:TransactionRelatedCostsMember 2016-01-01 2016-12-31 0001613859 prah:VestingBasedOnMarketConditionsRateOneMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001613859 prah:VestingBasedOnMarketConditionsRateOneMember us-gaap:EmployeeStockOptionMember 2016-03-02 2016-03-02 0001613859 prah:VestingBasedOnMarketConditionsRateOneMember us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0001613859 prah:VestingBasedOnServiceMember us-gaap:EmployeeStockOptionMember prah:TransactionRelatedCostsMember 2017-01-01 2017-12-31 0001613859 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0001613859 prah:VestingBasedOnMarketConditionsRateTwoMember us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0001613859 prah:RestrictedStockAwardsRsasAndRestrictedStockUnitsRsusMember prah:EmployeeMember 2018-01-01 2018-12-31 0001613859 us-gaap:EmployeeStockOptionMember prah:OmnibusPlanForKeyEmployees2014Member 2018-01-01 2018-12-31 0001613859 prah:RestrictedStockAwardsRsasAndRestrictedStockUnitsRsusMember us-gaap:DirectorMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-01-01 2018-12-31 0001613859 prah:VestingBasedOnServiceMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001613859 2013-09-23 2013-09-23 0001613859 prah:RestrictedStockAwardsRsasAndRestrictedStockUnitsRsusMember us-gaap:DirectorMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-01-01 2018-12-31 0001613859 us-gaap:EmployeeStockOptionMember prah:StockIncentivePlan2018Member 2018-01-01 2018-12-31 0001613859 us-gaap:EmployeeStockOptionMember 2013-09-23 2013-09-23 0001613859 prah:VestingBasedOnMarketConditionsRateTwoMember us-gaap:EmployeeStockOptionMember 2016-11-16 2016-11-16 0001613859 2018-05-31 0001613859 prah:VestingBasedOnMarketConditionsRateTwoMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001613859 prah:RestrictedStockAwardsRsasAndRestrictedStockUnitsRsusMember 2018-01-01 2018-12-31 0001613859 prah:RestrictedStockAwardsRsasAndRestrictedStockUnitsRsusMember 2017-12-31 0001613859 prah:RestrictedStockAwardsRsasAndRestrictedStockUnitsRsusMember 2018-12-31 0001613859 prah:VestingBasedOnMarketConditionsRateTwoMember us-gaap:EmployeeStockOptionMember 2013-12-01 2013-12-31 0001613859 2017-10-01 2017-12-31 0001613859 2018-10-01 2018-12-31 0001613859 us-gaap:StateAndLocalJurisdictionMember 2018-12-31 0001613859 prah:EmployeeHealthInsuranceMember 2018-01-01 2018-12-31 0001613859 prah:EmployeeHealthInsuranceMember 2018-12-31 0001613859 us-gaap:EmploymentContractsMember prah:SeniorVicePresidentMember 2018-01-01 2018-12-31 0001613859 prah:LitigationWithCityOfSaoPauloBrazilMember 2018-12-31 0001613859 prah:GeneralBusinessInsuranceMember 2018-01-01 2018-12-31 0001613859 prah:EmployeeHealthInsuranceMember 2017-12-31 0001613859 us-gaap:EmploymentContractsMember us-gaap:VicePresidentMember 2018-01-01 2018-12-31 0001613859 us-gaap:EmploymentContractsMember us-gaap:ExecutiveVicePresidentMember 2018-01-01 2018-12-31 0001613859 prah:LitigationWithCityOfSaoPauloBrazilMember 2018-01-01 2018-12-31 0001613859 us-gaap:EmploymentContractsMember us-gaap:ChiefExecutiveOfficerMember 2018-01-01 2018-12-31 0001613859 country:JP 2017-12-31 0001613859 country:DE 2017-12-31 0001613859 country:DE 2018-12-31 0001613859 country:JP 2018-12-31 0001613859 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2017-01-01 2017-12-31 0001613859 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2016-01-01 2016-12-31 0001613859 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2018-01-01 2018-12-31 0001613859 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0001613859 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001613859 us-gaap:InterestRateSwapMember 2013-10-02 0001613859 us-gaap:InterestRateSwapMember 2018-01-05 0001613859 prah:InterestRateSwapTwoMember 2015-06-30 0001613859 prah:InterestRateSwapTwoMember 2018-01-01 2018-12-31 0001613859 prah:InterestRateSwapTwoMember 2016-12-01 2016-12-31 0001613859 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-05 0001613859 us-gaap:InterestRateSwapMember 2018-01-01 2018-12-31 0001613859 srt:MaximumMember us-gaap:InterestRateSwapMember 2013-10-02 2013-10-02 0001613859 us-gaap:InterestRateSwapMember 2015-07-01 2015-09-30 0001613859 prah:InterestRateSwapTwoMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-05 0001613859 us-gaap:InterestRateSwapMember 2017-01-01 2017-12-31 0001613859 prah:InterestRateSwapTwoMember 2018-01-05 0001613859 us-gaap:InterestRateSwapMember 2016-01-01 2016-12-31 0001613859 srt:MinimumMember us-gaap:InterestRateSwapMember 2013-10-02 2013-10-02 0001613859 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2018-12-31 0001613859 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2015-12-31 0001613859 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesAttributableToNoncontrollingInterestMember 2015-12-31 0001613859 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0001613859 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0001613859 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-12-31 0001613859 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-12-31 0001613859 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0001613859 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2016-12-31 0001613859 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-12-31 0001613859 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0001613859 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesAttributableToNoncontrollingInterestMember 2016-12-31 0001613859 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0001613859 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0001613859 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesAttributableToNoncontrollingInterestMember 2018-12-31 0001613859 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2015-12-31 0001613859 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2017-12-31 0001613859 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesAttributableToNoncontrollingInterestMember 2017-12-31 0001613859 currency:CAD us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0001613859 currency:GBP us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0001613859 currency:GBP us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0001613859 currency:CAD us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0001613859 currency:RUB us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0001613859 currency:EUR us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0001613859 currency:EUR us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0001613859 currency:RUB us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0001613859 currency:CAD us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0001613859 currency:EUR us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0001613859 currency:GBP us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0001613859 currency:RUB us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0001613859 country:US 2018-12-31 0001613859 country:GB 2018-12-31 0001613859 country:NL 2017-12-31 0001613859 country:NL 2018-12-31 0001613859 prah:OtherAmericasMember 2017-12-31 0001613859 prah:OtherEuropeAfricaAsiaPacificMember 2017-12-31 0001613859 srt:AmericasMember 2017-12-31 0001613859 srt:AmericasMember 2018-12-31 0001613859 prah:OtherAmericasMember 2018-12-31 0001613859 country:GB 2017-12-31 0001613859 country:US 2017-12-31 0001613859 prah:EuropeAfricaAsiaPacificMember 2017-12-31 0001613859 prah:OtherEuropeAfricaAsiaPacificMember 2018-12-31 0001613859 prah:EuropeAfricaAsiaPacificMember 2018-12-31 0001613859 us-gaap:ServiceMember prah:OtherEuropeAfricaAsiaPacificMember 2018-01-01 2018-12-31 0001613859 us-gaap:ServiceMember country:GB 2018-01-01 2018-12-31 0001613859 us-gaap:ServiceMember prah:EuropeAfricaAsiaPacificMember 2018-01-01 2018-12-31 0001613859 us-gaap:ServiceMember srt:AmericasMember 2018-01-01 2018-12-31 0001613859 us-gaap:ServiceMember 2018-01-01 2018-12-31 0001613859 us-gaap:ServiceMember country:US 2018-01-01 2018-12-31 0001613859 us-gaap:ServiceMember prah:OtherAmericasMember 2018-01-01 2018-12-31 0001613859 us-gaap:ServiceMember country:NL 2018-01-01 2018-12-31 0001613859 us-gaap:ServiceMember 2017-01-01 2017-12-31 0001613859 us-gaap:ServiceMember country:NL 2016-01-01 2016-12-31 0001613859 us-gaap:ServiceMember srt:AmericasMember 2017-01-01 2017-12-31 0001613859 us-gaap:ServiceMember prah:OtherEuropeAfricaAsiaPacificMember 2016-01-01 2016-12-31 0001613859 us-gaap:ServiceMember country:US 2017-01-01 2017-12-31 0001613859 us-gaap:ServiceMember country:US 2016-01-01 2016-12-31 0001613859 prah:ReimbursementMember 2017-01-01 2017-12-31 0001613859 us-gaap:ServiceMember srt:AmericasMember 2016-01-01 2016-12-31 0001613859 us-gaap:ServiceMember 2016-01-01 2016-12-31 0001613859 us-gaap:ServiceMember prah:OtherEuropeAfricaAsiaPacificMember 2017-01-01 2017-12-31 0001613859 us-gaap:ServiceMember country:GB 2017-01-01 2017-12-31 0001613859 us-gaap:ServiceMember prah:EuropeAfricaAsiaPacificMember 2016-01-01 2016-12-31 0001613859 us-gaap:ServiceMember prah:OtherAmericasMember 2016-01-01 2016-12-31 0001613859 us-gaap:ServiceMember prah:EuropeAfricaAsiaPacificMember 2017-01-01 2017-12-31 0001613859 us-gaap:ServiceMember country:GB 2016-01-01 2016-12-31 0001613859 prah:ReimbursementMember 2016-01-01 2016-12-31 0001613859 us-gaap:ServiceMember country:NL 2017-01-01 2017-12-31 0001613859 us-gaap:ServiceMember prah:OtherAmericasMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableInvestigatorFeesMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableOutOfPocketCostsMember prah:DataSolutionsMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableOutOfPocketCostsMember prah:ClinicalResearchMember 2018-01-01 2018-12-31 0001613859 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:DataSolutionsMember 2018-01-01 2018-12-31 0001613859 us-gaap:MaterialReconcilingItemsMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ClinicalResearchMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableOutOfPocketCostsMember prah:DataSolutionsMember 2016-01-01 2016-12-31 0001613859 us-gaap:MaterialReconcilingItemsMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableOutOfPocketCostsMember 2018-01-01 2018-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableInvestigatorFeesMember prah:ClinicalResearchMember 2018-01-01 2018-12-31 0001613859 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember prah:ClinicalResearchMember 2018-01-01 2018-12-31 0001613859 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember prah:ClinicalResearchMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableOutOfPocketCostsMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:DataSolutionsMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:DirectCostsMember prah:ClinicalResearchMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableInvestigatorFeesMember prah:DataSolutionsMember 2018-01-01 2018-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ClinicalResearchMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember prah:DataSolutionsMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001613859 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember prah:DataSolutionsMember 2018-01-01 2018-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableOutOfPocketCostsMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember prah:DataSolutionsMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember 2018-01-01 2018-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ClinicalResearchMember 2018-01-01 2018-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:DirectCostsMember 2018-01-01 2018-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableInvestigatorFeesMember prah:ClinicalResearchMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableInvestigatorFeesMember prah:DataSolutionsMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:DirectCostsMember prah:ClinicalResearchMember 2018-01-01 2018-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:DirectCostsMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableOutOfPocketCostsMember prah:DataSolutionsMember 2018-01-01 2018-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableInvestigatorFeesMember prah:ClinicalResearchMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:DirectCostsMember prah:DataSolutionsMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableInvestigatorFeesMember prah:DataSolutionsMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:DataSolutionsMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableOutOfPocketCostsMember prah:ClinicalResearchMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableOutOfPocketCostsMember prah:ClinicalResearchMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableInvestigatorFeesMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:DirectCostsMember prah:DataSolutionsMember 2017-01-01 2017-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:DirectCostsMember prah:ClinicalResearchMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:DirectCostsMember prah:DataSolutionsMember 2018-01-01 2018-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:DirectCostsMember 2016-01-01 2016-12-31 0001613859 us-gaap:OperatingSegmentsMember prah:ReimbursableInvestigatorFeesMember 2018-01-01 2018-12-31 0001613859 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember prah:ClinicalResearchMember 2017-01-01 2017-12-31 0001613859 us-gaap:ServiceMember 2017-04-01 2017-06-30 0001613859 2017-01-01 2017-03-31 0001613859 2017-07-01 2017-09-30 0001613859 prah:ReimbursementMember 2017-04-01 2017-06-30 0001613859 us-gaap:ServiceMember 2017-07-01 2017-09-30 0001613859 us-gaap:ServiceMember 2017-10-01 2017-12-31 0001613859 2017-04-01 2017-06-30 0001613859 prah:ReimbursementMember 2017-01-01 2017-03-31 0001613859 us-gaap:ServiceMember 2017-01-01 2017-03-31 0001613859 prah:ReimbursementMember 2017-10-01 2017-12-31 0001613859 prah:ReimbursementMember 2017-07-01 2017-09-30 0001613859 2018-01-01 2018-03-31 0001613859 2018-04-01 2018-06-30 0001613859 2018-07-01 2018-09-30 0001613859 prah:SymphonyHealthSolutionsCorporationMember 2017-07-01 2017-09-30 0001613859 prah:VestingBasedOnServiceMember us-gaap:EmployeeStockOptionMember prah:TransactionRelatedCostsMember 2017-07-01 2017-09-30 0001613859 prah:TransactionRelatedCostsMember prah:SecondaryPublicOfferingMember 2017-07-01 2017-09-30 iso4217:USD xbrli:shares xbrli:pure prah:segment xbrli:shares iso4217:USD prah:derivative prah:employee prah:reportable_segments
Table of Contents


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 10‑K
 
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2018
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                  to                 .
Commission file number: 001‑36732
 
PRA Health Sciences, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
46‑3640387
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)

4130 ParkLake Avenue, Suite 400, Raleigh, NC 27612
(Address of principal executive offices) (Zip Code)
(919) 786‑8200
Registrant’s telephone number, including area code
 

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
    
Name of each exchange on which registered
Common Stock, par value $0.01 per share
 
Nasdaq Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None
 

Indicate by check mark if the registrant is a well‑known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒  No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐  No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S‑T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒  No ☐
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S‑K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10‑K or any amendment to this Form 10‑K. ☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b‑2 of the Exchange Act.
Large accelerated filer ☒
Accelerated filer ☐
Non-accelerated filer ☐
Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Act). Yes ☐  No ☒
The aggregate market value of the voting and non‑voting common equity held by non‑affiliates of the registrant, based upon the closing sale price as reported on the Nasdaq Global Select Market on June 30, 2018, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $4.7 billion. For purposes of this computation, shares of the registrant’s common stock held by affiliates, including executive officers, directors and certain holders known to the registrant, have been excluded.
Indicate the number of shares outstanding of each of the issuer’s classes of Common Stock, as of the latest practicable date.
Class
    
Number of Shares Outstanding
Common Stock $0.01 par value
 
65,531,659 shares outstanding as of February 22, 2019
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission relating to the 2019 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10‑K to the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.
 


Table of Contents


PRA HEALTH SCIENCES, INC.
ANNUAL REPORT ON FORM 10‑K
FOR FISCAL YEAR ENDED DECEMBER 31, 2018
TABLE OF CONTENTS
 
Item
Number
 
Page No.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

i

Table of Contents


FORWARD‑LOOKING STATEMENTS
 
This Annual Report on Form 10‑K, or this report, contains forward‑looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Such forward‑looking statements reflect, among other things, our current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward‑looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward‑looking statements and should be evaluated as such. Without limiting the foregoing, the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “should,” “targets,” “will” and the negative thereof and similar words and expressions are intended to identify forward‑looking statements. These forward‑looking statements are subject to a number of risks, uncertainties and assumptions, including those described in “Risk Factors” in Part I, Item 1A of this report, and speak only as of the date hereof. Unless legally required, we assume no obligation to update any such forward‑looking information to reflect actual results or changes in the factors affecting such forward‑looking information.
 
Market and Industry Data and Forecasts

This report includes data, forecasts and information obtained from industry publications and surveys and other information available to us. Forecasts and other metrics included in this report to describe our industry are inherently uncertain and speculative in nature, and actual results for any period may materially differ. Estimates and forecasts involve uncertainties and risks and are subject to change based on various factors, including those discussed above under “Forward-Looking Statements.” While we are not aware of any misstatements regarding the third-party industry data presented in this report, we have not independently verified any of the data from third-party sources, nor have we ascertained the underlying assumptions relied upon therein.

The ISR 2018 Market Report, as defined below, represents research opinion or viewpoints published by a market research firm Industry Standard Research. Such opinions or viewpoints should not be construed as statements of fact. The ISR 2018 Market Report speaks as of its original publication date (and not as of the date of this report) and the opinions expressed in the ISR 2018 Market Report are subject to change without notice. ISR does not endorse any vendor, product or service depicted in its research publications.

Website and Social Media Disclosure
 
We use our website (www.prahs.com) as a channel of distribution of company information. The information we post through this channel may be deemed material. Accordingly, investors should monitor this channel, in addition to following our press releases, Securities and Exchange Commission, or SEC, filings and public conference calls and webcasts. The contents of our website are not, however, a part of this report.

1

Table of Contents


Part I
 
Item 1.  Business
 
Overview
 
We are one of the world’s leading global contract research organizations, or CROs, by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. We believe we are one of a select group of CROs with the expertise and capability to conduct clinical trials across major therapeutic areas on a global basis. Our therapeutic expertise includes areas that are among the largest in pharmaceutical development, and we focus in particular on oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic and infectious diseases. We believe that we further differentiate ourselves from our competitors through our investments in medical informatics and clinical technologies designed to enhance efficiencies, improve study predictability and provide better transparency for our clients throughout their clinical development processes. Our Data Solutions segment allows us to better serve our clients across their entire product lifecycle by (i) improving clinical trial design, recruitment, and execution; (ii) creating real-world data solutions based on the use of medicines by actual patients in normal situations; and (iii) increasing the efficiency of biotechnology and pharmaceutical companies' commercial organizations through enhanced analytics and outsourcing services.  
 
Our global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 16,400 employees worldwide. Since 2000, we have participated in more than 3,800 clinical trials worldwide, worked on marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to U.S. Food and Drug Administration, or FDA, or international regulatory approval of more than 85 drugs.
 
We offer flexible clinical development service offerings, which include embedded and functional outsourcing services in addition to traditional, project‑based clinical trial services. Our Strategic Solutions offerings provide Embedded Solutions™ and functional outsourcing services in which our teams are fully integrated within the client’s internal clinical development operations and are responsible for managing functions across the entire breadth of the client’s drug development pipeline. We believe that our Strategic Solutions offerings represent an innovative alternative to the traditional, project‑based approach and allow our clients to maintain greater control over their clinical development processes. Our flexible clinical development service offerings expand our addressable market beyond the traditional outsourced clinical development market to include the clinical development spending that biopharmaceutical companies historically have retained in‑house.

Over the past 30 years, we have developed strong client relationships and have performed services for more than 300 biotechnology and pharmaceutical clients. Our Strategic Solutions offerings have significantly expanded our relationships with large pharmaceutical companies in recent years, which has allowed us to pursue strategic alliances with these companies due to our global presence, broad therapeutic expertise and flexible clinical development service offerings. Additionally, we believe that we have built a reputation as a strategic partner of choice for biotechnology and small‑ to mid‑sized pharmaceutical companies as a result of our competitively-differentiated platform and our long‑term track record of serving these companies.
 
CRO Industry
 
CROs provide drug development services, regulatory and scientific support, and infrastructure and staffing support to provide their clients with the flexibility to supplement their in‑house capabilities or to provide a fully outsourced solution. The CRO industry has grown from providing limited clinical trial services in the 1970s to a full-service industry characterized by broad relationships with clients and by service offerings that encompass the entire drug development process. Today, CROs provide a comprehensive range of clinical services, including protocol design and management and monitoring of Phase I through Phase IV clinical trials, data management, laboratory testing, medical and safety reviews and statistical analysis. In addition, CROs provide services that generate high quality and timely data in support of applications for regulatory approval of new drugs or reformulations of existing drugs as well as new and existing marketing claims. CROs leverage selected information technologies and procedures to efficiently capture, manage and analyze the large streams of data generated during a clinical trial.
 
Drug development processes
 
Discovering and developing new drugs is an expensive and time‑consuming process and is highly regulated and monitored through approval processes that vary by region. Before a new prescription drug reaches commercialization, it must undergo extensive pre‑clinical and clinical testing and regulatory review, to verify that the drug is safe and effective.

2

Table of Contents


 
A drug is first tested in pre‑clinical studies, which can take several years to complete. When a new molecule is synthesized or discovered, it is tested for therapeutic value using various animal and tissue models. If the drug warrants further development, additional studies are completed and an investigational new drug application, or IND, is submitted to the FDA. Once the IND becomes effective, the drug may proceed to the human clinical trial phase which generally consists of the following interrelated phases, which may overlap:
 
Stages of Clinical Development
 
 prah20161231x10k001a04.jpg

Market trends
 
Industry Standard Research, or ISR, a market research firm, estimated in its “2018 CRO Market Size Projections 2017-2022” report, or ISR 2018 Market Report, that the size of the worldwide CRO market was approximately $34 billion in 2017 and will grow at a 7.5% CAGR to $49 billion in 2022. This growth will be driven by an increase in the amount of research and development expenditure and levels of clinical development outsourcing by biopharmaceutical companies.
 
Increased R&D spending
 
ISR estimates in its 2018 Market Report that research and development, or R&D, expenditures by biopharmaceutical companies were approximately $293 billion in 2017 and will grow approximately 3% per year through 2022. Of this amount, approximately $121 billion was spent on development, including $86 billion on Phase I through IV clinical development. Growth drivers of R&D spending among biopharmaceutical companies include the need to replenish lost revenues resulting from the patent expirations of a large number of high‑profile drugs in recent years which has resulted in the need for biopharmaceutical companies to increase their R&D expenditures to eventually fill this revenue void with new drug approvals, and a healthy capital-raising environment among biotechnology companies in recent years. We believe biotechnology companies primarily use the capital to fund clinical trials, and due to the general lack of existing infrastructure, these trials are often contracted to CROs.

Higher outsourcing penetration
 
ISR estimates in its 2018 Market Report that approximately 40% of Phase I through IV of clinical development spend is outsourced to CROs, and the levels of penetration are expected to increase to approximately 47% by 2022. We believe this increase in outsourcing is due to several factors, including the need to maximize R&D productively, the increasing burden of clinical trial complexity, and the desire to pursue simultaneous registration in multiple countries.
 
Maximizing Productivity and Reducing Cost—Productivity within the biopharmaceutical industry has declined over the past several years and the cost of developing a new drug has significantly increased. The combined impact of declining R&D productivity and increased development costs has translated into significant pressure on margins and short‑term earnings for biopharmaceutical companies. We believe that the need for these companies to maximize

3

Table of Contents


productivity and lower costs will lead them to partner increasingly with CROs that can improve efficiency, and increase flexibility and speed across their clinical operations. 

Increasing Clinical Trial Complexity—Over the last decade, the burden of clinical trial complexity has been increasingly difficult to manage due to requirements from regulatory authorities worldwide for greater amounts of clinical trial and safety data to support the approval of new drugs, and requirements for adherence to increasingly complex and diverse regulations and guidelines. In an effort to minimize potential risks, these regulatory agencies also typically require a greater amount of post‑approval information and monitoring of drugs on the market. To balance the conflicting demands of a growing market with the need to control R&D expenses, biopharmaceutical companies partner with CROs that can provide services designed to generate high-quality and timely data in support of regulatory approvals of new drugs or the reformulations of existing drugs, as well as support of post‑approval regulatory requirements. 

Simultaneous Multi‑Country Registration—Given their desire to maximize efficiency and global market penetration to achieve higher potential returns on their R&D expenditures, biopharmaceutical companies are increasingly pursuing simultaneous, rather than sequential, regulatory new drug submissions and approvals in multiple countries. However, most biotechnology and small‑ to mid‑sized pharmaceutical companies do not possess the capability or capacity to simultaneously conduct large‑scale clinical trials in more than one country. In addition, establishing and maintaining internal global infrastructure to pursue multiple regulatory approvals in different therapeutic categories and jurisdictions can be costly.
 
Our History and Corporate Information
 
PRA Health Sciences, Inc. was incorporated in Delaware in June 2013. Our wholly‑owned subsidiary, PRA Holdings, Inc., or PRA Holdings, was incorporated in Delaware in July 2007 and its predecessors date back to 1982. Our qualified and experienced clinical and scientific staff has been delivering clinical drug development services to our clients for more than 30 years and our service offerings now encompass the spectrum of the clinical drug development process. See Note 4 to our audited consolidated financial statements found elsewhere in this Annual Report on Form 10-K for additional information with respect to our recent acquisitions.

Our Competitive Strengths
 
Global CRO platform
 
We are one of the largest CROs in the world by revenue focused on executing clinical trials on a global basis. Our global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and over 16,400 employees worldwide. We are dedicated to the seamless execution of integrated clinical trials on multiple continents concurrently. We believe our global presence and scale are important differentiators as biopharmaceutical companies are increasingly focused on greater patient access for increasingly complex clinical trials and gaining regulatory approval for new products in multiple jurisdictions simultaneously.
 
Broad and flexible service offering
 
We believe that we are one of a select group of CROs capable of providing both traditional, project‑based CRO services as well as embedded and functional outsourcing services. Our broad and flexible service offering allows us to meet the clinical research needs of a wide range of clients, from small biotechnology companies to large pharmaceutical companies. Through more than 30 years of experience, we have developed significant expertise executing complex drug development projects that span Phase I through Phase IV clinical trials. Our Product Registration offerings consist primarily of traditional, project‑based CRO services, where we have gained the reputation as a strategic partner of choice to biotechnology and pharmaceutical companies. Our Strategic Solutions offerings primarily cater to the needs of large pharmaceutical companies that seek to maintain greater control over their clinical trial processes.
 
Therapeutic expertise in large segments of drug development
 
Our therapeutic expertise encompasses areas that are among the largest in pharmaceutical development, including oncology, immunology, central nervous system, inflammation and infectious diseases. We have participated in more than 2,300 clinical trials in these key areas since 2005, accounting for a substantial majority of our total clinical trials during this period. We employ drug development experts with extensive experience across numerous therapeutic areas in preparing development plans, establishing study and protocol designs, identifying investigative sites and patients and submitting regulatory filings. Our

4

Table of Contents


staff is highly experienced and includes approximately 750 Ph.Ds, 600 medical doctors and 275 doctors of pharmacy worldwide.
 
Innovative approach to clinical trials using medical informatics
 
We are committed to being an industry leader in developing global, scalable and sustainable solutions for our clients. We aim to continuously improve our systems and processes by investing in medical informatics, technology, analytics and IT infrastructure. Our information delivery system enables rapid, web‑based delivery of clinical trial data to clients and project teams. We believe our proprietary analysis and application of this data are key differentiators and allow us to identify more productive investigative sites and speed up overall patient enrollment, thereby decreasing drug development timelines. We have invested in and acquired large databases of aggregated patient medical data, which we refer to as medical informatics, to better understand patient distribution and location. Specifically, we have acquired data sources that give us significant amounts of information about patient populations within the United States to enhance enrollment, including medical claims data, hospital master charge data, pharmacy data, laboratory data and payor data. Capitalizing on our investments in medical informatics, we have the capability to identify potential patient populations by location, diagnostic code, treating physician, medications, date diagnosed, last treatment and other relevant metrics. Our medical informatics suite includes physician, hospital and pharmacy databases that cover more than 280 million patient lives and approximately 10 billion patient and pharmacy claims in the United States.

Leading enabler of integrated health data and analytics

The acquisition of Symphony Health supports our commitment to enhancing the future of clinical development with best-in-class technology solutions which enable deep, data-driven insights to optimize global clinical studies and drug commercialization.    
 
Diversified and attractive client base
 
Over the past 30 years, we have developed strong client relationships and have performed services for more than 300 biotechnology and pharmaceutical clients. We have significantly expanded our relationships with large pharmaceutical companies in recent years, which has allowed us to pursue strategic alliances with these companies due to our global presence, broad therapeutic expertise and flexible clinical development service offerings. Additionally, we believe that we have built a reputation as a strategic partner of choice for biotechnology and small‑ to mid‑sized pharmaceutical companies as a result of our competitively differentiated platform and our long‑term track record of serving these companies. Our client relationships are also broad and diversified, and in the year ended December 31, 2018 our top 10 clients represented 56% of revenue, with our largest client representing approximately 9% of revenue and our largest single study accounting for approximately 3% of our revenue.
 
Innovative management team
 
We are led by a dedicated and experienced executive management team with an average of more than 20 years of experience across the global clinical research, pharmaceutical and life sciences industries. This team has been responsible for building our global platform, successfully integrating our acquisitions, developing our advanced IT‑enabled infrastructure and realizing our significant growth in revenue and earnings over the past five years.
 
Our Growth Strategy
 
Leverage our strong market position within the biotechnology and small‑ to mid‑sized pharmaceutical market
 
We believe our long‑term track record serving biotechnology and small‑ to mid‑sized pharmaceutical companies has resulted in our earning a reputation as a strategic partner of choice for these companies. We believe that biotechnology and small‑ to mid‑sized pharmaceutical companies rely on full service CROs to deliver fast, effective and thorough support throughout the clinical development and regulatory processes, as these companies generally lack a global clinical development infrastructure. We intend to leverage our strong relationships with biotechnology and small‑ to mid‑sized pharmaceutical companies to capture additional business from these companies. In particular, we believe the CRO strategic alliances that have become prevalent with large pharmaceutical companies over the past several years will increasingly be utilized by biotechnology and small‑ to mid‑sized pharmaceutical companies. We believe we are well-positioned to take advantage of these opportunities given the depth of our relationships and our proven track record serving these customers.
 

5

Table of Contents


Build deeper and broader relationships with large pharmaceutical companies
 
Large pharmaceutical companies have increasingly focused on partnering with multi‑national CROs that offer a wide array of global therapeutic and service capabilities. We have invested significantly in our global scale and infrastructure over the past several years to enhance our status as a service provider for these companies. Our acquisition of RPS significantly increased the depth of our relationships with large pharmaceutical companies. We intend to continue to expand our relationships beyond the Embedded Solutions provided through our Strategic Solutions offering to include traditional, project‑based clinical trial services.
 
Expand our leading therapeutic expertise in existing and new areas
 
We believe that our therapeutic expertise in all clinical phases of drug development is critical to the proper design and management of clinical trials and we intend to continue to capitalize on our strong market positions in several large therapeutic categories. We have established, and will continue to refine, our scientific and therapeutic business development initiatives, which link our organization to key clinical opinion leaders and medical informatics data to more effectively leverage therapeutic expertise throughout our client engagement. Specifically, we believe that oncology, central nervous system, inflammation and infectious diseases, which together represent the majority of all drug candidates currently in clinical development by biotechnology and pharmaceutical companies, will be significant drivers of our growth. In the area of oncology, we believe that the growth of targeted therapies, companion diagnostics and personalized medicine will continue to drive drug development. With the aging demographics, we believe we will see significant growth in the area of dementia and Alzheimer’s research and drug development, which is complemented by our specialty and focus in neurology. Additionally, we believe that development of niche therapeutic drugs (orphan drugs) will continue to see considerable growth moving forward and we have a dedicated staff focused on the design and conduct of trials for these drugs.
 
Continue to enhance our tech-enabled CRO engagement model

The acquisition of Symphony Health has provided us with rich data insights that will allow us to customize our clinical studies to be as unique as the patients who they are designed around. By creatively harnessing the power of our technology and data assets, we are redefining the clinical development process for a more patient-centric future.

Continue to realize strategic benefits from recent acquisitions
 
We believe we will continue to realize strategic benefits from the acquisitions we have completed over the past five years, resulting in additional revenue growth and margin improvements. We believe that our strategic acquisitions are complementary to our customer base and expect to generate incremental revenue growth by cross‑selling our full set of services to our existing and new customers, thereby expanding the scope of our customer relationships and generating additional revenue.
 
Pursue selective and complementary acquisition strategy
 
We are a selectively acquisitive company focused on growing our core service offerings, therapeutic capabilities and geographic reach into areas of high market growth. We have acquired 21 companies since 1997 and have established programs to help us identify acquisition targets and integrate them successfully. Our acquisition strategy is driven by our comprehensive commitment to serve client needs and we are continuously assessing the market for potential opportunities.
 
Service Offerings
 
We have two reportable segments: Clinical Research and Data Solutions. Our Clinical Research segment encompasses a broad array of services across the spectrum of clinical development programs. Our Data Solutions segment provides data, analytics, technology, and consulting solutions to the life sciences market. The offerings of our two segments complement each other and can provide enhanced value to our clients when delivered together, with each driving demand for the other.

For financial information regarding our segments, see Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Segment Results of Operations" and Note 20 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K.

Clinical Research


6

Table of Contents


We perform a broad array of services across the spectrum of clinical development programs, from the filing of INDs and similar regulatory applications to conducting all phases of clinical trials. Our core service offerings include:

Product Registration, which includes Phase IIb through III product registration trials and Phase IV trials, inclusive of post‑marketing commitments and registries;

Strategic Solutions, which provides Embedded Solutions and functional outsourcing services, in which our teams are fully integrated within the client’s internal clinical development operations and responsible for managing functions across the entire breadth of the client’s drug development pipeline; and

Early Development Services, which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.
 
We provide many back office services to clients as well, including processing the payments to investigators and volunteers. We also collaborate with third‑party vendors for services such as imaging, central lab and patient recruitment services.

Product Registration
 
Our Product Registration offerings encompass the design, management and implementation of study protocols for Phase II through Phase III clinical trials, which are the critical building blocks of product development programs, as well as Phase IV, or post‑approval, clinical trials. We have extensive resources and expertise to design and conduct studies on a global basis, develop integrated global product databases, collect and analyze trial data and prepare and submit regulatory submissions in the United States, Europe and other jurisdictions.

A typical full‑scale program or project may involve the following components:

clinical program development, review and consultation and lifecycle management planning;

design of the clinical protocol and electronic case report forms, or CRFs;

feasibility studies for investigator interest and patient access and availability;

patient recruitment and retention services;

project management;

investigator and site analysis for selection and qualification;

investigator handbook and meetings;

investigational site support and clinical monitoring;

data management;

patient medical and safety management;

analysis and reporting;

medical and scientific publications; and

preparation of regulatory filings.
 
As described below, we offer a suite of product registration service offerings to our clients to address the several components involved in conducting a full‑scale program or project.
 
Clinical Trial Management—Our clinical trial management services, used by biotechnology and pharmaceutical clients, may be performed exclusively by us or in collaboration with the client’s internal staff or other CROs. With our broad clinical trial management capabilities, we conduct single site studies, multi‑site U.S. and international studies and global studies

7

Table of Contents


on multiple continents. Through our electronic trial master file, we can create, collect, store, edit and retrieve any electronic document in any of our office locations worldwide, enabling our global project teams to work together efficiently regardless of where they are physically located and allowing seamless transfer of work to a more efficient locale.
 
Project Management—Our project management group manages the development process, setting specific targets and utilizing various metrics to ensure that a project moves forward in the right trajectory, resources are used optimally and client satisfaction is met. This group also oversees the implementation of a work breakdown structure, communication plan, and a risk and contingency program for each study. We believe that the management structure of our service delivery model sets us apart in the industry. Each individual project is assigned a director of project delivery and key strategic accounts are also assigned a general partner. As a member of the senior management team, the general partner works with the director of project delivery, the project management group and client representatives to ensure the highest level of client satisfaction. With approximately 370 project directors and project managers, we match our project management personnel to projects based on experience and study specific parameters.

Regulatory Affairs—Our team of global regulatory professionals has extensive experience working with biotechnology and pharmaceutical companies and regulatory authorities worldwide. Our regulatory affairs group is comprised of an internal network of local regulatory experts who are native speakers in countries across North America, Latin America, Western and Eastern Europe, Africa and Asia Pacific. Regulatory team members and local regulatory experts act as clients’ representatives for submissions and direct communications with regulatory authorities in all regions. The group’s regulatory expertise enables rapid study start‑up and facilitates competitive product development plans and effective submission strategies.
 
Therapeutic Expertise—Our therapeutic expertise group provides scientific and medical expertise and patient access and retention services worldwide across a broad range of therapeutic areas. Our broad experience throughout various therapeutic areas allows us to offer a more complete global service offering to our clients. Our diverse therapeutic expertise group leverages best‑in‑class data assets to assist our clients with the design and implementation of entire clinical development programs and our current and potential clients increasingly seek partners who can provide these capabilities. We provide clients with therapeutic expertise in the design and implementation of high‑quality product development programs and help them achieve key development milestones in a cost and time effective manner. Our therapeutic expertise is used by both emerging biotechnology companies that lack clinical development infrastructure and pharmaceutical companies that have limited internal medical resources or are exploring new therapeutic areas.
 
Clinical Operations—Our clinical operations group provides clients with a full set of study site management and monitoring services in approximately 90 countries worldwide, through our highly experienced team of clinical research associates and specialists. This experience includes knowledge of local regulations, medical practices, safety and individual therapeutic areas. We provide our clients with fully trained and locally based clinical teams led by experienced clinical team managers that initiate site start‑up, monitor activities and review data. Based in the Americas, Europe, Asia Pacific and Africa, these teams work from a strategic foundation that combines reliance on proven, consistent processes with the flexibility to adapt innovative ideas and technologies. Given our expertise executing clinical trials around the world, we are positioned to meet our clients’ diverse needs and expectations. Our study start‑up services group, a unit within clinical operations, manages the key components of rapid site activation and investigational site set‑up for clinical trials by utilizing our global and region specific expertise.
 
Data and Programming Services—Our global data and programming services group offers an innovative suite of technologies that gather and organize clinical trial data. We employ industry leading electronic data capture technologies and innovative delivery systems to produce high quality and standardized data and reports. We focus on evaluating a client’s needs, presenting optimal solutions for each trial and implementing the chosen solution effectively during project execution. To support these goals, we have built a group of technological experts in drug research that has a strong foundation in data management fundamentals and core programming abilities.
 
Safety and Risk Management—Our dedicated safety and risk management group helps clients design, implement and operationalize the proper safety procedures from development through to post‑marketing, allowing for clear assessment and the communication of patient safety profiles. We have centralized drug safety centers in Mannheim, Germany; Swansea, United Kingdom; Charlottesville, Virginia, United States (with a satellite center in Lenexa, Kansas); Sao Paulo, Brazil; and Singapore. Centers are staffed with experienced drug safety associates. These associates are responsible for integrating an effective risk minimization strategy for a drug product and generating useable information through ongoing risk evaluation. Our safety and risk management team provides risk mitigation strategies for our clients at all stages of the drug development cycle along with core signal detection capabilities.
 

8

Table of Contents


Biostatistics and Medical Writing—Our global biostatistics and medical writing operations integrate our biostatistics, medical writing, pharmacokinetics and regulatory publishing groups. With a staff of industry experienced and therapeutically trained biostatisticians and medical writers, we offer clients expertise in statistical analysis, data pooling and regulatory reporting. This global team provides specialist consulting expertise and support to clients from the first stage of protocol design through post‑marketing surveillance and Phase IV studies. For publishing, we use a specialized electronic system that enables us to seamlessly assemble, manage and publish complex documents in compliance with applicable regulatory guidelines.
 
Quality Assurance Services—Our global quality assurance group is staffed by a team of experienced professionals in the Americas, Europe and Asia Pacific. Our quality assurance department is entirely separate from and independent of the personnel engaged in the direction and conduct of clinical trials. The objective of the quality assurance group is the global promotion of ongoing quality awareness and continuous improvement of our processes. This group serves these efforts by performing audits on the processes and systems used in the management of clinical trials to ensure compliance with study protocol and applicable regulatory requirements. This group has performed audits for a wide range of medical indications and in all phases of clinical trials across the globe.
 
Late-Phase Services—Our global late-phase services group supports global and regional post‑approval trials with management locations centralized in Pennsylvania, Germany and Singapore. Our experienced late‑phase services team assists clients with the post‑marketing process by helping identify trends and signals in large populations as well as planning and conducting safety surveillance studies, large‑sample trials, registries, restricted access programs, risk management programs, diagnostic trials and biomarker research. The team consists of industry leading strategic experts, operational specialists and epidemiologists who work with clients to identify post‑marketing research objectives and goals and translate them into comprehensive study designs. 

Strategic Solutions
 
Our Strategic Solutions offerings allow biotechnology and pharmaceutical companies to execute their internally‑managed development portfolio with greater flexibility and to leverage their existing infrastructure to minimize redundancy. These offerings provide a broad spectrum of solutions that allow for the efficient management and execution of critical clinical development functions for pharmaceutical clients. These services are embedded or integrated within the client’s internal clinical development operations to support the entire breadth of the client’s drug development pipeline. By embedding our employees within our clients’ infrastructure, we create a strategic and interdependent relationship that allows us to anticipate our clients’ clinical trial demands and efficiently deploy our skilled clinical professionals to meet our clients’ needs. Clinical functions supported by this service offering include study start‑up activities, site monitoring, study management, data management, biostatistics, regulatory and product safety. We focus our solutions primarily on our clients’ Phase II through Phase IV development programs. While traditional, project‑based CRO offerings target the outsourced component of biopharmaceutical industry spending, our Strategic Solutions offerings address the total Phase II through IV development market. We pioneered the embedded services model described below, and we have extensive experience helping customers re‑align their operating model to more efficiently manage their development portfolio with greater flexibility and control.
 
Our Strategic Solutions offerings include:
 
Embedded Solutions—We believe we are the only company in the industry to offer a strategically scalable, fully‑embedded clinical development solution. Our Embedded Solutions model is designed to merge clinical operations expertise, management, infrastructure and support to create a flexible and integrated operating model. The goal of our Embedded Solutions model is to enable our clients’ internally‑managed development processes to be executed with greater flexibility. These solutions can be further enhanced by leveraging our systems and technology as required. In our Embedded Solutions model, we typically work with our partners to assist in redesigning existing systems and processes to drive greater efficiency, speed and quality and to implement innovative approaches and enhanced technology. We employ a strong joint governance structure and robust metrics to measure and ensure strong quality, cycle time, productivity and service‑level performance.
 
Functional Services Provider Solutions—Our functional services provider offering provides dedicated capacity management within a single operating platform and within one function or across multiple functions and geographies. While the customer provides direction and functional management, we provide resources and line management, training and support. We also utilize business level metrics to help ensure that staff are deployed with the relevant experience and are producing consistent, repeatable results.
 
Staff Augmentation Solutions—Our staff augmentation solutions offering provides clients with the ability to address their dynamic staffing needs by supplying access to resources qualified to meet their clinical development needs. This allows

9

Table of Contents


clients to maintain flexibility while also reducing fixed costs. In order to rapidly attract and recruit qualified employees for these situations, we have assembled what we believe is the largest team in the industry focused on personnel recruitment. These individual professionals are hired as our employees and are managed by our teams, minimizing co‑employment related issues. The customer has the ability to define the resources required according to the therapeutic‑ and disease‑specific experience required. These resources can be on site at the customer’s facility, at our offices, or regionally based.

Custom‑Built Development Solutions—Our custom‑built development solutions are designed to offer people, process, systems and development expertise that enable the efficient internal development of a company’s product portfolio with greater control and flexibility, accelerated development timelines and substantially reduced costs. With the client’s core leadership in control, we help to build the development team our clients need, while enabling them to maintain the flexibility to be nimble during the development lifecycle.
 
Commercialization Services—Through our commercialization services offering, we assist our clients in addressing the challenge of commercializing products. We do this by deploying professionals who are knowledgeable in launch preparation and product lifecycle management. We assist customers in managing the product lifecycle by working with them to create concise messaging, engage thought leadership and health care providers, generate consumer enthusiasm for the product, and prepare for post‑marketing commitments. Our commercialization services offering utilizes our flexible service model and, as such, can be delivered as an Embedded Solution, through our functional service provider model, or through staff augmentation.
 
Early Development Services
 
Our Early Development Services, or EDS, offerings include a full range of services for Phase I and Phase IIa studies as well as bioanalytical analysis. We have conducted studies for major pharmaceutical companies in Europe, the United States and Japan, as well as for many smaller and emerging biotechnology companies. We have also built direct relationships with a large base of available subjects, including healthy volunteers and patient populations with specific medical conditions.
 
Acquisitions in recent years have allowed us to significantly expand our Phase I to Phase II services. This includes offerings focused on the conduct and design of early stage patient population studies, and therapeutically focused in human abuse liability, or HAL, addiction, pain, psychiatric, neurological, pediatric and infectious disease services. We are one of the largest providers of patient population for Phase I and confined Phase II to Phase III services in the United States, and are one of only a few CROs in the world that has the ability to design and conduct HAL studies, a regulatory‑required study for central nervous system compounds. We believe this enables us to provide our clients with a full range of Phase I to Phase II clinical research services in specialized patient populations for both inpatient and outpatient settings.
 
EDS also supports a variety of additional services, ranging from protocol development to data management and pharmacy services, including manufacturing of investigational medicinal products. Our state‑of‑the‑art laboratories provide pharmacokinetics, the branch of pharmacology concerned with the movement of drugs within the body, and pharmacodynamics, the branch of pharmacology concerned with the effects of drugs and the mechanism of their action analyses, including biomarkers, as needed. Our safety laboratory supports our own clinics and also acts as a central lab for medium sized Phase II trials. We also provide clinical study reports, statistical analysis, medical writing and regulatory support.
 
We focus on high‑end Phase I studies and specialize in more complex types of studies in which safety, intelligent design, and a wide range of pharmacodynamics assessments are critical factors. We believe our Phase I team is a leader in new developments, such as microdosing studies, pain models, HAL studies and multi‑purpose protocols with adaptive designs. We have developed extensive methodologies enabling us to conduct studies with pharmacokinetics and/or pharmacodynamics objectives.
 
We have more than 1,200 early development specialists working in five clinical pharmacology units located across four different countries, including the United States, the Netherlands and countries in Central and Eastern Europe. We are equipped with the technologies and infrastructure for high‑quality, efficient studies on a wide range of drugs and indications. Over the past five years, we have conducted more than 700 high‑level, complex early development clinical trials and more than 250 bioanalytical studies per year over the previous five years.
 
Phase I through IIa Studies—For in‑house Phase I studies, we offer more than 420 beds worldwide and accommodate volunteers in our state‑of‑the‑art clinical pharmacology units, some of which are hospital-based. At these centers, volunteers are under constant medical supervision by a team of highly experienced medical professionals. We have a pool of more than 100,000 study participants (both healthy volunteers and various specific patient populations).


10

Table of Contents


In addition to in‑house studies, we use an innovative “unit‑on‑demand” business model that brings a Phase I center to patients. This model establishes a Phase I study environment in central medical facilities that specialize in the treatment of the target patient population. Physicians can recruit high volumes of patients using extensive networks of referring specialists and general practitioners. The studies occur in single center and multi‑national settings. We have also built an extensive patient network and database in areas including depression, schizophrenia, diabetes and hepatitis C. In addition to conducting Phase I and IIa studies in subjects, these sites act as investigative sites in Phase IIb and III trials.
 
We also offer full pharmacy capabilities and we operate a manufacturing site that complies with applicable current Good Manufacturing Practice regulations and is designed for fast and flexible manufacturing of small batches of investigational medicinal product for studies. In addition, dedicated data management professionals who can process clinical data into specific deliverables are integrated in each clinical pharmacology unit.
 
Since a large proportion of drug compounds do not succeed in Phase I, we utilize IND trials that include “microdose” or “low‑dose” studies to screen multiple candidates at an early stage and minimize the number of failing clinical product candidates. We have been closely involved in the field of microdose studies over the past ten years and have conducted more than 30 microdose studies.
 
Bioanalytical Laboratory—We offer clients two state‑of‑the‑art bioanalytical laboratories located in Assen, the Netherlands, and Lenexa, Kansas, United States. These bioanalytical laboratories have been harmonized with respect to standard operating procedures, work instructions and equipment. This provides a high level of consistency, continuity and efficiency. It also provides our clients with the ability to run studies in either laboratory, depending on the requirements of the study, and ensures that they will receive the same high level of service. Both bioanalytical laboratories are located within close proximity to their respective Phase I clinical pharmacology unit, ensuring rapid sample processing for critical dose escalation decision making involving pharmacokinetic assays. Both facilities include laboratories for mass spectrometry and ultra‑ performance liquid chromatography, typically applied to small molecule analysis. For large molecules, such as biologicals and biomarkers, our laboratories operate a wide variety of specialized assays, including ligand binding assays with a variety of detection methodologies and immunogenicity. In our fully licensed isotope laboratory, bioanalytical support is provided for mass balance and microdosing studies. The laboratories, combined with expert and highly educated staff, provide a full range of analytical services throughout the development process.

Data Solutions

Our Data Solutions segment provides data, analytics, technology, and consulting solutions to the life sciences market. We have proprietary sources of data about pharmaceutical transactions that we purchase from pharmaceutical retailers, prescribers, payers and institutional users. The data is anonymized and includes details on the patient, the location where they purchased the drug or therapy, and the payer. The details on the patient, although anonymous, are tracked in such a way as to allow analysis of therapies and purchasing over a long term. They also include demographic data such as age, gender, race and diagnoses. The data is refreshed monthly.

The core service offerings of our Data Solutions segment include:

Market Intelligence Services

Targeting and Compensation - Prescription and drug sales data services used primarily to compensate sales representatives. This data includes dispensed prescription data, non-retail pharmacy drug purchasing data and healthcare demographic and affiliations data.

Pharmaceutical Audit Suite - National-level prescription and sales data services used primarily for market research. Data subscriptions include all products and therapeutic areas and are primarily accessed on-line through our business intelligence tool.

Consulting & Services

Brand Analytics - Anonymized patient-level data sets and services that enable a variety of commercial analytics, including patient compliance, persistency, product switching, share and counts, and diagnosis. The most significant offering is PatientSource, a comprehensive patient-level data set, providing a detailed view of patient treatment activity in a client-defined disease category. PatientSource includes data regarding prescribers, patients and payer dynamics.


11

Table of Contents


Managed Markets - A suite of prescription claims-based data products and analytic tools that leverage our exclusive claims lifecycle data to understand managed markets' influence on product demand.

Commercial Effectiveness - A professional services unit providing offerings that enable clients to optimize promotion spend and activities. Offerings include digital promotional measurement, advanced targeting, patient journey, and market landscape.

Scientific Studies/Clinical Hubs - A unit providing services that include clinically-oriented data hubs and health economics studies to pharmaceutical companies' medical affairs or health economics divisions. Our team provides real world evidence data to support the assessment of the clinical effectiveness of drugs.

Apps & Technology

Health Data Services - Technology-enabled products and services that allow clients to access and analyze effectively Symphony Health and integrated third-party data.

Clients and Suppliers
 
We serve a wide range of client types, including biotechnology and pharmaceutical companies. We have developed numerous strategic relationships in the last five years. In the year ended December 31, 2018, we derived 48% of our revenue from large pharmaceutical companies, 16% of our revenue from small‑ to mid‑sized pharmaceutical companies, 18% of our revenue from large biotechnology companies, 17% of our revenue from all other biotechnology companies and 1% of our revenue from non-pharmaceutical companies. In 2018 our top five clients represented approximately 36% of revenue; this revenue was derived from a combination of fixed‑fee contracts, fee‑for‑service contracts and time and materials contracts. No individual client or project accounted for 10% or more of revenue for the year ended December 31, 2018.
 
We utilize a number of suppliers in our business, including data suppliers, central laboratory services, drug storage and shipping, foreign language translation services and information technology. In 2018, our largest individual supplier was paid $23.3 million. In addition, our top 10 suppliers together received payments during 2018 of approximately $137.1 million. We believe that we will continue to be able to meet our current and future supply needs.
 
Sales and Marketing
 
We have a proven sales team with the ability to build relationships with new clients and to grow within existing clients. Critical to our sales process is the involvement of our operations and global scientific and medical affairs teams who contribute their knowledge to project implementation strategies presented in client proposals. These teams also work closely with the sales team to build long‑term relationships with biotechnology and pharmaceutical companies. Our therapeutic expertise team supports the sales effort by developing robust service offerings in its core therapeutic areas, which link our organization to key clinical opinion leaders, global investigator networks and best‑in‑class vendors. We rely heavily on our past project performance, qualified teams, medical informatics data and therapeutic expertise in winning new business.
 
Our approach to proposal development, led by seasoned proposal developers in conjunction with insight from our drug development experts, allows us to submit proposals that address client requirements in a creative and tailored manner. Proposal teams conduct research on competing drugs and conduct feasibility studies among potential investigators to assess their interest and patient availability for proposals and presentations. Our proprietary, automated estimation system allows for rapid and accurate creation of project budgets, which forms the initial basis for business management of budgets subsequent to award of the study.
 
Competition
 
Our Clinical Research business competes primarily with other full‑service CROs and in‑house research and development departments of pharmaceutical and established biotech companies. Our principal traditional CRO competitors are ICON plc, IQVIA Holdings Inc., Laboratory Corporation of America Holdings, PAREXEL International Corporation, Pharmaceutical Product Development LLC, and Syneos Health, Inc.
 
CROs compete on the basis of a number of factors, including reliability, past performance, expertise and experience in specific therapeutic areas, scope of service offerings, strengths in various geographic markets, technological capabilities, ability to manage large scale global clinical trials, and price.

12

Table of Contents


 
The CRO industry remains highly fragmented, with several hundred smaller, limited service providers and a small number of full‑service companies with global capabilities. We believe there are significant barriers to becoming a global provider offering a broad range of services and products. These barriers include:
the cost and experience necessary to develop broad therapeutic expertise;
the ability to manage large, complex international clinical programs;
the ability to deliver high‑quality services consistently for large drug development projects;
the experience to prepare regulatory submissions on a global basis; and
the infrastructure and knowledge to respond to the global needs of clients.
 
Our Data Solutions business competes with a diverse set of businesses. We generally compete with other information, analytics, technology, services and consulting companies, as well as with government agencies, private payers and other healthcare companies that provide their data directly to others. Our offerings compete with a number of firms, including IQVIA Inc., OptumHealth, Cognizant Technology Solutions, and ZS Associates.

Backlog
 
Our studies and projects are performed over varying durations, ranging from several months to several years. Backlog represents anticipated service revenue from contracted new business awards that either have not started or are in process but have not been completed for our Clinical Research segment. Canceled contracts and scope reductions are removed from backlog as they occur. Our backlog at December 31, 2018, 2017 and 2016 was approximately $4.2 billion, $3.5 billion and $2.9 billion, respectively. Cancellations totaled $378.8 million, $366.0 million and $290.6 million for the years ended December 31, 2018, 2017 and 2016, respectively.
 
We believe our backlog as of any date is not necessarily a meaningful indicator of our future results for a variety of reasons. First, studies vary in duration. For instance, some studies that are included in our backlog may be completed in 2019, while others may be completed in later years. Second, the scope of studies may change, which may either increase or decrease the amount of backlog. Third, studies may be terminated or delayed at any time by the client or regulatory authorities. Delayed contracts remain in our backlog until a determination of whether to continue, modify or cancel the study is made.

We had $2,644.8 million, $2,413.7 million and $2,076.5 million in net new business awards for our Clinical Research segment in the years ended December 31, 2018, 2017, and 2016, respectively. Net new business represents gross new business awards less cancellations for the period.

We exclude our Data Solutions segment from backlog and new business awards due to the short term nature of its contracts.

For more details regarding risks related to our backlog, see “Risk Factors—Our backlog may not convert to service revenue at the historical conversion rate.”
 
Intellectual Property
 
We develop and use proprietary methodologies, analytics, systems, technologies and other intellectual property throughout our business, including a number of patents as well as other proprietary information regarding our methodologies, technologies, systems and analytics. We rely upon a combination of legal, technical, and administrative safeguards to protect our proprietary and confidential information and trade secrets, and patent, copyright and trademark laws to protect other intellectual property rights. We also hold various federal trademark registrations and pending applications in the United States and other jurisdictions, including PRA Health Sciences, Nextrials, Parallel 6, and Symphony Health. Trademarks and service marks generally may be renewed indefinitely so long as they are in use and/or their registrations are properly maintained, and so long as they have not been found to have become generic. The technology and other intellectual property rights owned and licensed by us are important to our business, although our management believes that our business, as a whole, is not dependent upon any one intellectual property or group of such properties.
 
Government Regulation
 

13

Table of Contents


In the United States, the FDA governs the conduct of clinical trials of drug products in human subjects, the form and content of regulatory applications, including, but not limited to, IND applications for human clinical testing, and the development, approval, manufacture, safety, labeling, storage, record keeping, and marketing of drug products. The FDA has similar authority and similar requirements with respect to the clinical testing of biological products and medical devices. In the European Union, or EU, similar laws and regulations apply which may vary slightly from one member state to another and are enforced by the European Medicines Agency or respective national member states’ authorities, depending on the case.

 Governmental regulation directly affects our business. Increased regulation leads to more complex clinical trials and an increase in potential business for us. Conversely, a relaxation in the scope of regulatory requirements, such as the introduction of simplified marketing applications for pharmaceutical and biological products, could decrease the business opportunities available to us.
 
We must perform our clinical drug and biologic services in compliance with applicable laws, rules and regulations, including “Good Clinical Practices,” or GCP, which govern, among other things, the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials. Before a human clinical trial may begin, the manufacturer or sponsor of the clinical product candidate must file an IND with the FDA, which contains, among other things, the results of preclinical tests, manufacturer information, and other analytical data. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development. Each clinical trial must be conducted in accordance with an effective IND. In addition, under GCP, each human clinical trial we conduct is subject to the oversight of an independent institutional review board, or IRB, which is an independent committee that has the regulatory authority to review, approve and monitor a clinical trial. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the study subjects are being exposed to an unacceptable health risk. In the EU, we must perform our clinical drug services in compliance with similar laws and regulations.
 
In order to comply with GCP and other regulations, we must, among other things:
comply with specific requirements governing the selection of qualified investigators;
obtain specific written commitments from the investigators;
obtain IRB review and approval of the clinical trial;
verify that appropriate patient informed consent is obtained before the patient participates in a clinical trial;
ensure adverse drug reactions resulting from the administration of a drug or biologic during a clinical trial are medically evaluated and reported in a timely manner;
monitor the validity and accuracy of data;
verify drug or biologic accountability;
instruct investigators and study staff to maintain records and reports; and
permit appropriate governmental authorities access to data for review.
 
We must also maintain reports in compliance with applicable regulatory requirements for each study for auditing by the client and regulatory authorities.
 
A failure to comply with applicable regulations relating to the conduct of clinical trials or the preparation of marketing applications could lead to a variety of sanctions. For example, violations of GCP could result, depending on the nature of the violation and the type of product involved, in the issuance of a warning letter, suspension or termination of a clinical study, refusal of the FDA to approve clinical trial or marketing applications or withdrawal of such applications, injunction, seizure of investigational products, civil penalties, criminal prosecutions, or debarment from assisting in the submission of new drug applications.
 
We monitor our clinical trials to test for compliance with applicable laws and regulations in the United States and the non‑U.S. jurisdictions in which we operate. We have adopted standard operating procedures that are designed to satisfy regulatory requirements and serve as a mechanism for controlling and enhancing the quality of our clinical trials. In the United States, our procedures were developed to ensure compliance with GCP and associated guidelines. Within Europe, all work is carried out in accordance with the Guideline for Good Clinical Practice ICH E6 (R2) adopted by the European Medicines Agency as EMA/CHMP/ICH/135/95. In order to facilitate global clinical trials, we have implemented common standard operating procedures across our regions to assure consistency whenever feasible.
 

14

Table of Contents


The Standards for Privacy of Individually Identifiable Health Information, or the Privacy Rule, and the Security Rule, issued under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health, or HITECH, Act of 2009, collectively HIPAA, as well as applicable state privacy and security laws and regulations, restrict the use and disclosure of certain protected health information, or PHI, and establish standards to protect individuals’ electronic PHI that is created, received, used or maintained by certain entities. Under the Privacy Rule, “covered entities” may not use or disclose PHI without the authorization of the individual who is the subject of the PHI, unless such use or disclosure is specifically permitted by the Privacy Rule or required by law.
 
We are not a covered entity under HIPAA. However, in connection with our clinical development activities, we do receive PHI from covered entities subject to HIPAA. In order for those covered entities to disclose PHI to us, the covered entity must obtain an authorization from the research subject that meets the Privacy Rule requirements, or make such disclosure pursuant to an exception to the Privacy Rule’s authorization requirement. We are both directly and indirectly affected by the privacy provisions surrounding individual authorizations because many investigators with whom we are involved in clinical trials are directly subject to them as a HIPAA “covered entity” and because we obtain identifiable health information from third parties that are subject to such regulations. Because of amendments to the HIPAA data security and privacy rules, there are some instances where we may be a HIPAA “business associate” of a “covered entity,” meaning that we may be directly liable for any breaches in PHI and other HIPAA violations. As part of our research activities, we require covered entities that perform research activities on our behalf to comply with HIPAA, including the Privacy Rule’s authorization requirement, and applicable state privacy and security laws and regulations.
 
In Europe, the European Union General Data Protection Regulation, or the EU GDPR, requires organizations working with the personal data of EU citizens to have established processes related to its collection and use. Organizations must have objective evidence of compliance (Principle of Accountability) with the EU GDPR. The penalties for non-compliance are significant, including up to four percent of an organization's global annual revenue. There are also administrative penalties where transfers of personal data may be stopped. As PRA is a global organization, such a disruption in data transfers could pose significant operational challenges.

We maintain applicable registrations with the Drug Enforcement Administration, or DEA, that enable us to use controlled substances in connection with our research services. Controlled substances are those drugs and drug products that appear on one of five schedules promulgated and administered by DEA under the Controlled Substances Act. This act governs, among other things, the distribution, recordkeeping, handling, security, and disposal of controlled substances. Our DEA registrations authorize us to receive, conduct testing on, and distribute controlled substances in Schedules II through V. A failure to comply with the DEA’s regulations governing these activities could lead to a variety of sanctions, including the revocation or the denial of a renewal of our DEA registration, injunctions, or civil or criminal penalties.
 
Environmental Regulation and Liability
 
We are subject to various laws and regulations relating to the protection of the environment and human health and safety in the countries in which we do business, including laws and regulations governing the management and disposal of hazardous substances and wastes, the cleanup of contaminated sites and the maintenance of a safe workplace. Our operations include the use, generation, and disposal of hazardous materials and medical wastes. We may, in the future, incur liability under environmental statutes and regulations for contamination of sites we own or operate (including contamination caused by prior owners or operators of such sites), the off‑site disposal of hazardous substances and for personal injuries or property damage arising from exposure to hazardous materials from our operations. We believe that we have been and are in substantial compliance with all applicable environmental laws and regulations and that we currently have no liabilities under such environmental requirements that could reasonably be expected to materially harm our business, results of operations or financial condition.

Liability and Insurance
 
We may be liable to our clients for any failure to conduct their studies properly according to the agreed‑upon protocol and contract. If we fail to conduct a study properly in accordance with the agreed‑upon procedures, we may have to repeat a study or a particular portion of the services at our expense, reimburse the client for the cost of the services and/or pay additional damages.
 

15

Table of Contents


At our clinical pharmacology units, we study the effects of drugs on healthy volunteers. In addition, in our clinical business we, on behalf of our clients, contract with physicians who render professional services, including the administration of the substance being tested, to participants in clinical trials, many of whom are seriously ill and are at great risk of further illness or death as a result of factors other than their participation in a trial. As a result, we could be held liable for bodily injury, death, pain and suffering, loss of consortium, or other personal injury claims and medical expenses arising from a clinical trial. In addition, we sometimes engage the services of vendors necessary for the conduct of a clinical trial, such as laboratories or medical diagnostic specialists. Because these vendors are engaged as subcontractors, we are responsible for their performance and may be held liable for damages if the subcontractors fail to perform in the manner specified in their contract.
 
To reduce our potential liability, and as a requirement of the GCP regulations, informed consent is required from each volunteer and patient. In addition, our clients provide us with contractual indemnification for all of our service related contracts. These indemnities generally do not, however, protect us against certain of our own actions such as those involving negligence or misconduct. Our business, financial condition and operating results could be harmed if we were required to pay damages or incur defense costs in connection with a claim that is not indemnified, that is outside the scope of an indemnity or where the indemnity, although applicable, is not honored in accordance with its terms.
 
We maintain errors, omissions, and professional liability insurance in amounts we believe to be appropriate. This insurance provides coverage for vicarious liability due to negligence of the investigators who contract with us, as well as claims by our clients that a clinical trial was compromised due to an error or omission by us. If our insurance coverage is not adequate, or if insurance coverage does not continue to be available on terms acceptable to us, our business, financial condition, and operating results could be materially harmed.
 
Seasonality

Although our business is not generally seasonal, our Clinical Research segment typically experiences a slight decrease in its revenue growth rate during the fourth quarter due to holiday vacations and a similar decrease in new business awards in the first quarter due to our clients’ budgetary cycles and vacations during the year‑end holiday period. Our Data Solutions segment usually experiences an increase in revenue during the fourth quarter as many pharmaceutical companies use a portion of funds remaining in their annual budgets to purchase its data offerings.

Employees
 
As of December 31, 2018, we had over 16,400 employees, of which approximately 43% were in the United States, approximately 34% were in Europe, approximately 3% were in Canada, and approximately 20% were in Africa, Latin America, and Asia Pacific. Some of our employees located outside of the United States are represented by workers council or labor unions. We believe that our employee relations are satisfactory. Approximately 40% of employees hold a Master’s level degree or higher. We have approximately 1,800 employees that hold a Ph.D, M.D. or other doctorate level degrees.
 
Available Information
 
We are subject to the informational requirements of the Exchange Act and, in accordance therewith, file reports, including annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission, or the SEC. Copies of our annual reports on Form 10‑K, quarterly reports on Form 10‑Q, current reports on Form 8‑K and our proxy statements for our annual meetings of stockholders, and any amendments or supplements to those reports, as well as Section 16 reports filed by our insiders, are available free of charge on our website as soon as reasonably practicable after we file the reports with, or furnish the reports to the SEC. Our website address is http://www.prahs.com, and our investor relations website is located at investor.prahs.com. Information on our website is not incorporated by reference herein. In addition, the SEC maintains an Internet site (http://www.sec.gov) containing reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.


16

Table of Contents


Item 1A.  Risk Factors
 
You should consider carefully the risks and uncertainties described below together with the other information included in this Annual Report on Form 10‑K, including our consolidated financial statements and related notes thereto. The occurrence of any of the following risks may materially and adversely affect our business, financial condition, results of operations and future prospects, which could in turn materially affect the price of our common stock.
 
The potential loss, delay or non‑renewal of our contracts, or the non‑payment by our clients for services that we have performed, could adversely affect our results.
 
We routinely experience termination, cancellation and non‑renewals of contracts by our clients in the ordinary course of business, and the number of cancellations can vary significantly from year to year.
 
Most of our clients for traditional, project‑based clinical trial services can terminate our contracts without cause upon 30 to 60 days’ notice. For example, our cancellation percentage for traditional, project‑based Phase I through IV trials was 17% and 18% for the years ended December 31, 2018 and 2017, respectively. Our traditional, project‑based clients may delay, terminate or reduce the scope of our contracts for a variety of reasons beyond our control, including but not limited to:
 
decisions to forgo or terminate a particular clinical trial;
lack of available financing, budgetary limits or changing priorities;
actions by regulatory authorities;
production problems resulting in shortages of the drug being tested;
failure of the drug being tested to satisfy safety requirements or efficacy criteria;
unexpected or undesired clinical results;
insufficient patient enrollment in a trial;
insufficient investigator recruitment;
decisions to downsize product development portfolios;
dissatisfaction with our performance, including the quality of data provided and our ability to meet agreed upon schedules;
shift of business to another CRO or internal resources;
product withdrawal following market launch; or
shut down of our clients’ manufacturing facilities.
 
In addition, our clients for our Strategic Solutions offerings may elect not to renew our contracts for a variety of reasons beyond our control, including in the event that we are unable to provide staff sufficient in number or experience as required for a project.
 
In the event of termination, our contracts often provide for fees for winding down the study, but these fees may not be sufficient for us to maintain our profit margins, and termination or non‑renewal may result in lower resource utilization rates, including with respect to personnel who we are not able to place on another client engagement.
 
Clinical trials can be costly and a material portion of our revenue is derived from emerging biotechnology and small to mid‑sized pharmaceutical companies, which may have limited access to capital. In addition, we provide services to such companies before they pay us for some of our services. There is a risk that we may initiate a clinical trial for a client, and the client subsequently becomes unwilling or unable to fund the completion of the trial. In such a situation, notwithstanding the client’s ability or willingness to pay for or otherwise facilitate the completion of the trial, we may be legally or ethically bound to complete or wind down the trial at our own expense.
 
Because the contracts included in our backlog can generally be terminated without cause, we do not believe that our backlog as of any date is necessarily a meaningful predictor of future results. In addition, we may not realize the full benefits of our backlog of contractually committed services if our clients cancel, delay or reduce their commitments under our contracts with them. For the reasons described above, the loss or delay of a large contract or the loss or delay of multiple contracts or a

17

Table of Contents


clients' non-payment for services could adversely affect our service revenue and profitability. In addition, the terminability of our contracts puts increased pressure on our quality control efforts, since not only can our contracts be terminated by clients as a result of poor performance, but any such termination may also affect our ability to obtain future contracts from the client involved and others. We believe the risk of loss or delay of multiple contracts is even greater in those cases where we are party to broader partnering arrangements with global biopharmaceutical companies.
 
We bear financial risk if we underprice our fixed‑fee contracts or overrun cost estimates, and our financial results can also be adversely affected by failure to receive approval for change orders or delays in documenting change orders.
 
Most of our traditional, project‑based Phase I through IV contracts are fixed‑fee contracts. We bear the financial risk if we initially underprice our contracts or otherwise overrun our cost estimates. In addition, contracts with our clients are subject to change orders, which we commonly experience and which occur when the scope of work we perform needs to be modified from that originally contemplated by our contract with the client. Modifications can occur, for example, when there is a change in a key trial assumption or parameter, a significant change in timing or a change in staffing needs. Furthermore, if we are not successful in converting out‑of‑scope work into change orders under our current contracts, we bear the cost of the additional work. Such underpricing, significant cost overruns or delay in documentation of change orders could have a material adverse effect on our business, results of operations, financial condition or cash flows.
 
Our backlog may not convert to revenue at the historical conversion rate.
 
Backlog represents anticipated revenue from contracted new business awards, excluding reimbursable out-of-pocket costs or reimbursable investigator fees, that either have not started or are in process but have not been completed. Our backlog was $4.2 billion, $3.5 billion, and $2.9 billion at December 31, 2018, 2017, and 2016, respectively. Our revenue conversion rate is based on a financial and operational analysis performed by our project management teams and represents the level of effort expected to be expended at a specific point in time. Once work begins on a project, revenue is recognized over the duration of the project. Projects may be terminated or delayed by the client or delayed by regulatory authorities for reasons beyond our control. To the extent projects are delayed, the timing of our revenue could be affected. In the event that a client cancels a contract, we generally would be entitled to receive payment for all services performed up to the cancellation date and subsequent client authorized services related to terminating the canceled project. Generally, however, we have no contractual right to the full amount of the revenue reflected in our backlog in the event of a contract cancellation. The duration of the projects included in our backlog, and the related revenue recognition, range from a few months to many years. Our backlog may not be indicative of our future results, and we may not realize all the anticipated future revenue reflected in our backlog. A number of factors may affect the realization of our revenue from backlog, including:
the size, complexity and duration of the projects;
the cancellation or delay of projects; and
change in the scope of work during the course of a project.
Fluctuations in our reported backlog levels also result from the fact that we may receive a small number of relatively large orders in any given reporting period that may be included in our backlog. Revenue recognition on larger, more global projects could be slower than on smaller, less global projects for a variety of reasons, including but not limited to, an extended period of negotiation between the time the project is awarded to us and the actual execution of the contract, as well as an increased time frame for obtaining the necessary regulatory approvals.

The relationship of backlog to realized revenues is indirect and may vary over time. As we increasingly compete for and enter into large contracts that are more global in nature, there can be no assurance about the rate at which our backlog will convert into revenue. A decrease in this conversion rate would mean that the rate of revenue recognized on contracts may be slower than what we have experienced in the past, which could materially and adversely impact our revenue and results of operations on a quarterly and annual basis. Additionally, delayed projects will remain in backlog and will not generate revenue at the rate originally expected, which could impair our cash flows and results of operations in the short term. Because of these large orders, our backlog in that reporting period may reach levels that may not be sustained in subsequent reporting periods.
 
Our operating margins and profitability will be adversely affected if we are unable to either achieve efficiencies in our operating expenses or grow revenues at a rate faster than expenses.
 
We operate in a highly competitive environment and experience competitive pricing pressure. To achieve our operating margins over the last three years, we have implemented initiatives to control the rate of growth of our operating expenses. We will continue to utilize these initiatives in the future with a view to offsetting these pricing pressures; however, we cannot be certain that we will be able to achieve the efficiency gains necessary to maintain or grow our operating margins or

18

Table of Contents


that the magnitude of our growth in service revenue will be faster than the growth in our operating costs. If we are unable to grow our service revenue at a faster rate than our operating costs, our operating margins will be adversely affected. Our initiatives and any future cost initiatives may also adversely affect us, as they may decrease employee morale or make it more difficult for us to meet operational requirements.
 
If we are unable to attract suitable investigators and patients for our clinical trials, our clinical development business may suffer.
 
The recruitment of investigators and patients for clinical trials is essential to our business. Patients typically include people from the communities in which the clinical trials are conducted. Our clinical development business could be adversely affected if we are unable to attract suitable and willing investigators or patients for clinical trials on a consistent basis. For example, if we are unable to engage investigators to conduct clinical trials as planned or enroll sufficient patients in clinical trials, we may need to expend additional funds to obtain access to resources or else be compelled to delay or modify the clinical trial plans, which may result in additional costs to us. These considerations might result in our being unable to successfully achieve our projected development timelines, or potentially even lead us to consider the termination of ongoing clinical trials or development of a product.
 
Our embedded and functional outsourcing solutions could subject us to significant employment liability.
 
With our embedded and functional outsourcing services, we place employees at the physical workplaces of our clients. The risks of this activity include claims of errors and omissions, misuse or misappropriation of client proprietary information, theft of client property and torts or other claims under employment liability, co‑employment liability or joint employment liability. We have policies and guidelines in place to reduce our exposure to such risks, but if we fail to follow these policies and guidelines we may suffer reputational damage, loss of client relationships and business, and monetary damages.

If we lose the services of key personnel or are unable to recruit experienced personnel, our business could be adversely affected.
 
Our success substantially depends on the collective performance, contributions and expertise of our senior management team and other key personnel, including qualified management, professional, scientific and technical operating staff and qualified sales representatives for our contract sales services. There is significant competition for qualified personnel in the biopharmaceutical services industry, particularly those with higher educational degrees, such as a medical degree, a Ph.D or an equivalent degree. The departure of any key executive, the payment of increased compensation to attract and retain qualified personnel, or our inability to continue to identify, attract and retain qualified personnel or replace any departed personnel in a timely fashion, may impact our ability to grow our business and compete effectively in our industry and may negatively affect our ability to meet financial and operational goals. Furthermore, clients or other companies seeking to develop in‑house capabilities may hire some of our senior management or key employees. We cannot assure you that a court would enforce the non‑competition provisions in our employment agreements.

Changes in accounting standards may adversely affect our financial statements.

From time to time the Financial Accounting Standards Board, or FASB, and SEC issue new or revised guidance that we are required to adopt. It is possible that future accounting standards may require changes to our current accounting treatment and may require us to make changes to our accounting systems and processes. These changes could have a material impact on our business, results of operations and financial condition. See Note 2 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details regarding recently implemented accounting standards and recently issued accounting pronouncements and the potential impact they may have on the Company. 

Our effective income tax rate may fluctuate for different reasons, including the U.S. Tax Cuts and Jobs Act enacted in 2017, which may adversely affect our operations, earnings and earnings per share.
 
Our effective income tax rate is influenced by our projected profitability in the various taxing jurisdictions in which we operate. The global nature of our business increases our tax risks. In addition, as a result of increased funding needs by governments resulting from fiscal stimulus measures, revenue authorities in many of the jurisdictions in which we operate are known to have become more active in their tax collection activities. Changes in the distribution of profits and losses among taxing jurisdictions may have a significant impact on our effective income tax rate, which in turn could have an adverse effect on our net income and earnings per share. The application of tax laws in various taxing jurisdictions, including the United States, is subject to interpretation, and tax authorities in various jurisdictions may have diverging and sometimes conflicting

19

Table of Contents


interpretations of the application of tax laws. Changes in tax laws or tax rulings in the United States or other tax jurisdictions in which we operate, could materially impact our effective tax rate.
 
Factors that may affect our effective income tax rate include, but are not limited to:

the requirement to exclude from our quarterly worldwide effective income tax calculations losses in jurisdictions where no income tax benefit can be recognized;

actual and projected full year pre‑tax income, including differences between actual and anticipated income before taxes in various jurisdictions;

changes in tax laws, or in the interpretation or application of tax laws, in various taxing jurisdictions, including the U.S. Tax Cuts and Jobs Act;

audits or other challenges by taxing authorities; and

the establishment of valuation allowances against a portion or all of certain deferred income tax assets if we determined that it is more likely than not that future income tax benefits will not be realized.
In addition, our effective income tax rate is influenced by U.S. tax law which has been substantially modified by the U.S. Tax Cuts and Jobs Act. The following provisions of the U.S. Tax Cuts and Jobs Act could have an adverse effect on our tax rate if it is determined that the provisions are applicable to the Company:
global intangible low-taxed income;          
limitations on the U.S. deductions for net business interest;
base erosion anti-abuse provisions; and
performance-based compensation subject to $1 million limit.
These changes may cause fluctuations in our effective income tax rate that could adversely affect our results of operations and cause fluctuations in our earnings and earnings per share.
 
Our business depends on the continued effectiveness and availability of our information systems, including the information systems we use to provide our services to our clients, and failures of these systems may materially limit our operations.
 
Due to the global nature of our business and our reliance on information systems to provide our services, we have increased, and intend to continue to increase, our use of web‑enabled and other integrated information systems in delivering our services. We also provide access to similar information systems to certain of our clients in connection with the services we provide them. As the breadth and complexity of our information systems continue to grow, we will increasingly be exposed to the risks inherent in the development, integration and ongoing operation of evolving information systems, including:
disruption, impairment or failure of data centers, telecommunications facilities or other key infrastructure platforms;
security breaches of, cyberattacks on and other failures or malfunctions in our critical application systems or their associated hardware; and
excessive costs, excessive delays or other deficiencies in systems development and deployment.
The materialization of any of these risks may impede the processing of data, the delivery of databases and services, and the day‑to‑day management of our business and could result in the corruption, loss or unauthorized disclosure of proprietary, confidential or other data. While we have disaster recovery plans in place, they might not adequately protect us in the event of a system failure. Despite any precautions we take, damage from fire, floods, hurricanes, power loss, telecommunications failures, computer viruses, information system security breaches and similar events at our various computer facilities could result in interruptions in the flow of data to our servers and from our servers to our clients. Corruption or loss of data may result in the need to repeat a trial at no cost to the client, but at significant cost to us, or result in the termination of a contract or damage to our reputation. Additionally, significant delays in system enhancements or inadequate performance of new or upgraded systems once completed could damage our reputation and harm our business. Finally, long‑term disruptions in the infrastructure caused by events such as natural disasters, the outbreak of war, the escalation of hostilities and acts of terrorism, particularly involving cities in which we have offices, could adversely affect our business.

20

Table of Contents


Although we carry property and business interruption insurance, our coverage might not be adequate to compensate us for all losses that may occur.

A failure or breach of our IT systems or technology could result in sensitive customer information being compromised or otherwise significantly disrupt our business operations, which would negatively materially affect our reputation and/or results of operations.

In the current environment, there are numerous and evolving risks to cybersecurity and privacy, including criminal hackers, hacktivists, state-sponsored intrusions, industrial espionage, employee malfeasance and human or technological error. High-profile security breaches at other companies and in government agencies have increased in recent years, and security industry experts and government officials have warned about the risks of hackers and cyberattacks targeting businesses such as ours. Computer hackers and others routinely attempt to breach the security of technology products, services and systems, and to fraudulently induce employees, customers, or others to disclosure information or unwittingly provide access to systems or data. Unauthorized disclosure of sensitive or confidential data, whether through system failure or employee negligence, fraud or misappropriation, could damage our reputation and cause us to lose clients. Similarly, unauthorized access to or through our information systems or those we develop for our clients, whether by our employees or third parties, including a cyberattack by computer programmers and hackers who may develop and deploy viruses, worms or other malicious software programs, could result in negative publicity, loss of client confidence, significant remediation costs, time-consuming and costly regulatory investigations, legal liability and damage to our reputation, and could have a material adverse effect on our results of operations. In addition, our liability insurance might not be sufficient in type or amount to adequately cover us against claims related to security breaches, cyberattacks and other related breaches. To date, cybersecurity attacks directed at us have not had a material impact on our financial results. Our clients are also increasingly requiring cybersecurity protections and mandating cybersecurity standards in our products, and we may incur additional costs to comply with such demands. While we have certain cybersecurity safeguards in place designed to protect and preserve the integrity of our information technology systems, due to the evolving nature of security threats, however, the impact of any future incidents cannot be predicted.
 
Upgrading the information systems that support our operating processes and evolving the technology platform for our services pose risks to our business.
 
Continued efficient operation of our business requires that we implement standardized global business processes and evolve our information systems to enable this implementation. We have continued to undertake significant programs to optimize business processes with respect to our services. Our inability to effectively manage the implementation and adapt to new processes designed into these new or upgraded systems in a timely and cost‑effective manner may result in disruption to our business and negatively affect our operations.
 
We have entered into agreements with certain vendors to provide systems development and integration services that develop or license to us the IT platform for programs to optimize our business processes. If such vendors fail to perform as required or if there are substantial delays in developing, implementing and updating the IT platform, our client delivery may be impaired, and we may have to make substantial further investments, internally or with third parties, to achieve our objectives. Additionally, our progress may be limited by parties with existing or claimed patents who seek to enjoin us from using preferred technology or seek license payments from us.
 
Meeting our objectives is dependent on a number of factors which may not take place as we anticipate, including obtaining adequate technology-enabled services, creating IT‑enabled services that our clients will find desirable and implementing our business model with respect to these services. Also, increased IT‑related expenditures may negatively impact our profitability.
 
Our operations might be affected by the occurrence of a natural disaster or other catastrophic event.
 
We depend on our clients, investigators, laboratories and other facilities for the continued operation of our business. Although we have contingency plans in place for natural disasters or other catastrophic events, these events, including terrorist attacks, pandemic flu, hurricanes and ice storms, could nevertheless disrupt our operations or those of our clients, investigators and collaboration partners, which could also affect us. In particular, our headquarters are in Raleigh, North Carolina where hurricanes might occur. Even though we carry business interruption insurance policies and typically have provisions in our contracts that protect us in certain events, we might suffer losses as a result of business interruptions that exceed the coverage available under our insurance policies or for which we do not have coverage. Any natural disaster or catastrophic event affecting us or our clients, investigators or collaboration partners could have a significant negative impact on our operations and financial performance.

21

Table of Contents


 
We may be adversely affected by client concentration or concentration in therapeutic classes in which we conduct clinical trials.
 
We derive a substantial portion of our revenues from a limited number of large clients. In 2018, we derived 36% of our revenue from our top five clients. In addition, almost 43% of our backlog, as of December 31, 2018, is concentrated among five clients. If any large client decreases or terminates its relationship with us, our business, results of operations or financial condition could be materially adversely affected.
 
Additionally, we conduct multiple clinical trials for different clients in single therapeutic classes, particularly in the areas of oncology and immunology. Conducting multiple clinical trials for different clients in a single therapeutic class involving drugs with the same or similar chemical action has in the past, and may in the future, adversely affect our business if some or all of the trials are canceled because of new scientific information or regulatory judgments that affect the drugs as a class or if industry consolidation results in the rationalization of drug development pipelines.
 
Our business is subject to international economic, political and other risks that could negatively affect our results of operations and financial condition.
 
We have significant operations in non‑U.S. countries that may require complex arrangements to deliver services on global contracts for our clients. Additionally, we have established operations in locations remote from our most developed business centers. As a result, we are subject to heightened risks inherent in conducting business internationally, including the following:
 
conducting a single trial across multiple countries is complex, and issues in one country, such as a failure to comply with local regulations or restrictions, may affect the progress of the trial in the other countries, for example, by limiting the amount of data necessary for a trial to proceed, resulting in delays or potential cancellation of contracts, which in turn may result in loss of revenue; 
non‑U.S. countries could enact legislation or impose regulations or other restrictions, including unfavorable labor regulations or tax policies, which could have an adverse effect on our ability to conduct business in or expatriate profits from those countries;
tax rates in certain non‑U.S. countries may exceed those in the United States and non‑U.S. earnings may be subject to withholding requirements or the imposition of tariffs, exchange controls or other restrictions, including restrictions on repatriation;
certain non‑U.S. countries are expanding or may expand their regulatory framework with respect to patient informed consent, protection and compensation in clinical trials, which could delay or inhibit our ability to conduct trials in such jurisdictions or which could materially increase the risks associated with performing trials in such jurisdictions;
the regulatory or judicial authorities of non‑U.S. countries may not enforce legal rights and recognize business procedures in a manner to which we are accustomed or would reasonably expect;
we may have difficulty complying with a variety of laws and regulations in non‑U.S. countries, some of which may conflict with laws in the United States;
changes in political and economic conditions may lead to changes in the business environment in which we operate, as well as changes in non‑U.S. currency exchange rates;
a prolonged shutdown of the U.S. federal government may hinder the growth of the U.S. economy, thus negatively affecting our business;
the adoption and expansion of trade restrictions, the occurrence or escalation of a “trade war,” or other governmental action related to tariffs or trade agreements or policies among the governments of the United States and other countries, such as Mexico or China, could adversely impact demand for our services, our costs, our clients, and the U.S. economy;
regulatory changes and economic conditions leading up to and following “Brexit” (the United Kingdom’s exit from the European Union), including uncertainties as to its timing and its effect on trade laws, tariffs and taxes, could create instability and volatility in the global financial and currency markets, conflicting or redundant regulatory regimes in Europe (such as the European Medicines Agency ("EMA") relocation from the United Kingdom to the Netherlands) and political instability;

22

Table of Contents


clients in non‑U.S. jurisdictions may have longer payment cycles, and it may be more difficult to collect receivables in non‑U.S. jurisdictions; and
natural disasters, pandemics or international conflict, including terrorist acts, could interrupt our services, endanger our personnel or cause project delays or loss of trial materials or results.
These risks and uncertainties could negatively impact our ability to, among other things, perform large, global projects for our clients. Furthermore, our ability to deal with these issues could be affected by applicable U.S. laws and the need to protect our assets. In addition, we may be more susceptible to these risks as we enter and continue to target growth in emerging countries and regions, including India, China, Eastern Europe and Latin America, which may be subject to a relatively higher risk of political instability, economic volatility, crime, corruption and social and ethnic unrest, all of which are exacerbated in many cases by a lack of an independent and experienced judiciary and uncertainties in how local law is applied and enforced. The materialization of any such risks could have an adverse impact on our financial condition and results of operations.
 
Due to the global nature of our business, we may be exposed to liabilities under the Foreign Corrupt Practices Act and various non‑U.S. anti‑corruption laws, and any allegation or determination that we violated these laws could have a material adverse effect on our business.
 
We are required to comply with the U.S. Foreign Corrupt Practices Act, or FCPA, and other U.S. and non‑U.S. anti‑corruption laws, which prohibit companies from engaging in bribery, including corruptly or improperly offering, promising, or providing money or anything else of value to non‑U.S. officials and certain other recipients. In addition, the FCPA imposes certain books, records, and accounting control obligations on public companies and other issuers. We operate in parts of the world in which corruption can be common and compliance with anti‑bribery laws may conflict with local customs and practices. Our global operations face the risk of unauthorized payments or offers being made by employees, consultants, sales agents, and other business partners outside of our control or without our authorization. It is our policy to implement safeguards to prohibit these practices by our employees and business partners with respect to our operations. However, irrespective of these safeguards, or as a result of monitoring compliance with such safeguards, it is possible that we or certain other parties may discover or receive information at some point that certain employees, consultants, sales agents, or other business partners may have engaged in corrupt conduct for which we might be held responsible. Violations of the FCPA or other non‑U.S. anti‑corruption laws may result in restatements of, or irregularities in, our financial statements as well as severe criminal or civil sanctions, and we may be subject to other liabilities, which could negatively affect our business, operating results and financial condition. In some cases, companies that violate the FCPA may be debarred by the U.S. government and/or lose their U.S. export privileges. Changes in anti‑corruption laws or enforcement priorities could also result in increased compliance requirements and related costs which could adversely affect our business, financial condition and results of operations. In addition, the U.S. or other governments may seek to hold us liable for successor liability FCPA violations or violations of other anti‑corruption laws committed by companies in which we invest or that we acquired or will acquire.
 
If we are unable to successfully develop and market new services or enter new markets, our growth, results of operations and financial condition could be adversely affected.
 
A key element of our growth strategy is the successful development and marketing of new services and entering new markets that complement or expand our existing business. As we develop new services or enter new markets, including services targeted at participants in the broader healthcare industry, we may not have or adequately build the competencies necessary to perform such services satisfactorily, may not receive market acceptance for such services or may face increased competition. If we are unable to succeed in developing new services, entering new markets or attracting a client base for our new services or in new markets, we will be unable to implement this element of our growth strategy, and our future business, reputation, results of operations and financial condition could be adversely affected.
 

23

Table of Contents


If we fail to perform our services in accordance with contractual requirements, government regulations and ethical considerations, we could be subject to significant costs or liability and our reputation could be adversely affected.
 
We contract with biotechnology and pharmaceutical companies to perform a wide range of services to assist them in bringing new drugs to market. Our services include monitoring clinical trials, laboratory analysis, electronic data capture, patient recruitment, data analytics, technology solutions and other related services. Such services are complex and subject to contractual requirements, government regulations, and ethical considerations. For example, we are subject to regulation by the FDA and comparable non‑U.S. regulatory authorities relating to our activities in conducting pre‑clinical and clinical trials. The clinical trial process must be conducted in accordance with regulations promulgated by the FDA under the Federal Food, Drug and Cosmetic Act, which requires the drug to be tested and studied in certain ways. In the United States, before human clinical testing may begin, a manufacturer must file an IND with the FDA. Further, an IRB for each medical center proposing to participate in the clinical trial must review and approve the protocol for the clinical trial before the medical center’s investigators participate. Once initiated, clinical trials must be conducted pursuant to and in accordance with the applicable IND, the requirements of the relevant IRBs, and GCP regulations. Similarly, before clinical trials begin, a drug is tested in pre‑clinical studies that are expected to comply with Good Laboratory Practice requirements. We are also subject to regulation by the DEA which regulates the distribution, recordkeeping, handling, security, and disposal of controlled substances. If we fail to perform our services in accordance with these requirements, regulatory authorities may take action against us. Such actions may include injunctions or failure to grant marketing approval of products, imposition of clinical holds or delays, suspension or withdrawal of approvals, rejection of data collected in our studies, license revocation, product seizures or recalls, operational restrictions, civil or criminal penalties or prosecutions, damages or fines. Clients may also bring claims against us for breach of our contractual obligations and patients in the clinical trials and patients taking drugs approved on the basis of those trials may bring personal injury claims against us. Any such action could have a material adverse effect on our results of operations, financial condition and reputation.
 
Such consequences could arise if, among other things, the following occur:
 
Improper performance of our services.  The performance of clinical development services is complex and time‑consuming. For example, we may make mistakes in conducting a clinical trial that could negatively impact or obviate the usefulness of the trial or cause the results of the trial to be reported improperly. If the trial results are compromised, we could be subject to significant costs or liability, which could have an adverse impact on our ability to perform our services and our reputation would be harmed. As examples:
non‑compliance generally could result in the termination of ongoing clinical trials or the disqualification of data for submission to regulatory authorities;
compromise of data from a particular trial, such as failure to verify that adequate informed consent was obtained from patients, could require us to repeat the trial under the terms of our contract at no further cost to our client, but at a potentially substantial cost to us; and
breach of a contractual term could result in liability for damages or termination of the contract. 
Large clinical trials can cost tens of millions of dollars, and while we endeavor to contractually limit our exposure to such risks, improper performance of our services could have a material adverse effect on our financial condition, damage our reputation and result in the cancellation of current contracts by the affected client or other current clients or failure to obtain future contracts from the affected client or other current or potential clients.
 
Investigation of clients.  From time to time, one or more of our clients are investigated by regulatory authorities or enforcement agencies with respect to regulatory compliance of their clinical trials, programs or the marketing and sale of their drugs. In these situations, we have often provided services to our clients with respect to the clinical trials, programs or activities being investigated, and we are called upon to respond to requests for information by the authorities and agencies. There is a risk that either our clients or regulatory authorities could claim that we performed our services improperly or that we are responsible for clinical trial or program compliance. If our clients or regulatory authorities make such claims against us and prove them, we could be subject to damages, fines or penalties. In addition, negative publicity regarding regulatory compliance of our clients’ clinical trials, programs or drugs could have an adverse effect on our business and reputation.
 

24

Table of Contents


If we fail to comply with certain healthcare laws, including fraud and abuse laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.
 
Even though we do not order healthcare services or bill directly to Medicare, Medicaid or other third‑party payors, certain federal and state healthcare laws and regulations pertaining to fraud and abuse are and will be applicable to our business. We could be subject to healthcare fraud and abuse laws of both the federal government and the states in which we conduct our business. Because of the breadth of these laws and the narrowness of available statutory and regulatory exceptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If we or our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, imprisonment and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results.
 
Our services could subject us to potential liability that may adversely affect our results of operations and financial condition.
 
Our business involves the testing of new drugs on patients in clinical trials. Our involvement in the clinical trial and development process creates a risk of liability for personal injury to or death of patients, particularly those with life‑threatening illnesses, resulting from adverse reactions to the drugs administered during testing or after regulatory approval. For example, we may be sued in the future by individuals alleging personal injury due to their participation in clinical trials and seeking damages from us under a variety of legal theories. If we are required to pay damages or incur defense costs in connection with any personal injury claim that is outside the scope of indemnification agreements we have with our clients, if any indemnification agreement is not performed in accordance with its terms or if our liability exceeds the amount of any applicable indemnification limits or available insurance coverage, our financial condition, results of operations and reputation could be materially and adversely affected. We might also not be able to obtain adequate insurance or indemnification for these types of risks at reasonable rates in the future.
 
We also contract with physicians to serve as investigators in conducting clinical trials. Investigators are typically located at hospitals, clinics or other sites and supervise the administration of the investigational drug to patients during the course of a clinical trial. If the investigators commit errors or make omissions during a clinical trial that result in harm to trial patients or if the investigators commit errors or make omissions in the administration of a drug to a patient, claims for personal injury or products liability damages may result. Additionally, if the investigators engage in fraudulent or negligent behavior, trial data may be compromised, which may require us to repeat the clinical trial or subject us to liability or regulatory action. We do not believe we are legally responsible for the medical care rendered by such third‑party investigators, and we would vigorously defend any claims brought against us. However, it is possible we could be found liable for claims with respect to the actions of third‑party investigators.
 
Some of our services involve direct interaction with clinical trial patients and operation of Phase I and IIa clinical facilities, which could create potential liability that may adversely affect our results of operations and financial condition.
 
We operate facilities where Phase I to IIa clinical trials are conducted, which ordinarily involve testing an investigational drug on a limited number of individuals to evaluate its safety, determine a safe dosage range and identify side effects. Failure to operate such a facility in accordance with applicable regulations could result in disruptions to our operations. Additionally, we face risks associated with adverse events resulting from the administration of such drugs and the professional malpractice of medical care providers. We also directly employ nurses and other trained employees who assist in implementing the testing involved in our clinical trials, such as drawing blood from subjects. Any professional malpractice or negligence by such investigators, nurses or other employees could potentially result in liability to us in the event of personal injury to or death of a subject in clinical trials. This liability, particularly if it were to exceed the limits of any indemnification agreements and insurance coverage we may have, may adversely affect our financial condition, results of operations and reputation.
 
Our insurance may not cover all of our indemnification obligations and other liabilities associated with our operations.
 
We maintain insurance designed to provide coverage for ordinary risks associated with our operations and our ordinary indemnification obligations. The coverage provided by such insurance may not be adequate for all claims we may make or may be contested by our insurance carriers. If our insurance is not adequate or available to pay liabilities associated with our operations, or if we are unable to purchase adequate insurance at reasonable rates in the future, our profitability may be adversely impacted.

 

25

Table of Contents


Exchange rate fluctuations may affect our results of operations and financial condition.
 
During 2018, approximately 16% of our revenue and 35% of our operating expenses were denominated in currencies other than the U.S. dollar, particularly the Euro and the British pound. Because a portion of our revenue and expenses are denominated in currencies other than the U.S. dollar and our financial statements are reported in U.S. dollars, changes in non‑U.S. currency exchange rates could significantly affect our results of operations and financial condition.
 
The revenue and expenses of our non‑U.S. operations are generally denominated in local currencies and translated into U.S. dollars for financial reporting purposes. Accordingly, exchange rate fluctuations will affect the translation of non‑U.S. results into U.S. dollars for purposes of reporting our consolidated results.
 
We are subject to non‑U.S. currency transaction risk for fluctuations in exchange rates during the period of time between the consummation and cash settlement of a transaction. We earn revenue from our service contracts over a period of several months and, in some cases, over several years. Accordingly, exchange rate fluctuations during this period may affect our profitability with respect to such contracts.
 
We may limit these risks through exchange rate fluctuation provisions stated in our service contracts, or we may hedge our transaction risk with non‑U.S. currency exchange contracts or options. We have not, however, hedged any of our non‑U.S. currency transaction risk, and we may experience fluctuations in financial results from our operations outside the United States and non‑U.S. currency transaction risk associated with our service contracts.
 
If we do not keep pace with rapid technological changes, our services may become less competitive or obsolete.
 
The biopharmaceutical industry generally, and drug development and clinical research more specifically, are subject to rapid technological changes. Our current competitors or other businesses might develop technologies or services that are more effective or commercially attractive than, or render obsolete, our current or future technologies and services. If our competitors introduce superior technologies or services and if we cannot make enhancements to remain competitive, our competitive position would be harmed. If we are unable to compete successfully, we may lose clients or be unable to attract new clients, which could lead to a decrease in our revenue and financial condition.
 
Our relationships with existing or potential clients who are in competition with each other may adversely impact the degree to which other clients or potential clients use our services, which may adversely affect our results of operations.
 
The biopharmaceutical industry is highly competitive, with companies each seeking to persuade payors, providers and patients that their drug therapies are more cost‑effective than competing therapies marketed or developed by competing firms. In addition to the adverse competitive interests that biopharmaceutical companies have with each other, these companies also have adverse interests with respect to drug selection and reimbursement with other participants in the healthcare industry, including payors and providers. Biopharmaceutical companies also compete to be first to the market with new drug therapies. We regularly provide services to biopharmaceutical companies that compete with each other, and we sometimes provide services to such clients regarding competing drugs in development. Our existing or future relationships with our biopharmaceutical clients have in the past deterred, and may continue to deter, other biopharmaceutical clients from using our services or, in certain instances, have resulted in our clients seeking to place limits on our ability to serve their competitors and other industry participants. In addition, our further expansion into the broader healthcare market may adversely impact our relationships with biopharmaceutical clients, and such clients may elect not to use our services, reduce the scope of services that we provide to them or seek to place restrictions on our ability to serve clients in the broader healthcare market with interests that are adverse to theirs. Any loss of clients or reductions in the level of revenues from a client could have a material adverse effect on our results of operations, business and prospects.

The biopharmaceutical services industry is fragmented and highly competitive.
 
The biopharmaceutical services industry is fragmented and highly competitive and if we do not compete successfully, our business will suffer. We often compete for business with other biopharmaceutical services companies, universities, niche providers and discovery and development departments within our clients, some of which are large biopharmaceutical services companies in their own right with greater resources than ours. As part of our business model, we have formed preferred vendor relationships. These relationships generally are not contractual and are subject to change at any time. As a result of these relationships, we may find reduced access to certain potential clients due to preferred vendor arrangements with other competitors. There are few barriers to entry for smaller specialized companies. Because of their size and focus, these companies might compete effectively against larger companies like us, which could have a material adverse impact on our business. Additionally, the industry is highly fragmented, with numerous smaller specialized companies and a handful of

26

Table of Contents


full‑service companies with global capabilities similar to ours. Increased competition has led to price and other forms of competition, which may result in acceptance of less favorable contract terms that could adversely affect our operating results. As a result of competitive pressures, in recent years our industry has experienced consolidation. This trend is likely to produce more competition from the resulting larger companies for both clients and acquisition candidates.

If we are unable to manage our joint ventures and identify, acquire and integrate future acquisitions and joint ventures with our existing business, services and technologies, our business, results of operations and financial condition could be adversely impacted.
 
We have historically grown our business both organically and through acquisitions, and we anticipate that a portion of our future growth may come from acquiring existing businesses, services or technologies and entering into strategic alliances and joint ventures. The success of any acquisition will depend upon, among other things, our ability to effectively integrate acquired personnel, operations, products and technologies into our business, to obtain regulatory approvals, and to retain the key personnel and clients of our acquired businesses. Failure to successfully integrate any acquired business may result in reduced levels of revenue, earnings or operating efficiency than might have been achieved if we had not acquired such businesses. In addition, any future acquisitions could result in the incurrence of additional debt and related interest expense, contingent liabilities and amortization expenses related to intangible assets, which could have a material adverse effect on our business, financial condition, operating results and cash flow.
 
The success of any joint venture will involve, among other things, learning about new markets and regulations, ensuring quality controls are adequate and not inadvertently creating competitors. We may be unable to identify suitable acquisition opportunities, properly evaluate the price of such acquisitions or obtain any necessary financing on commercially acceptable terms. We may also spend time and money investigating and negotiating with potential acquisition targets and strategic alliance partners but not complete the transaction. Acquisitions involve other risks, including, among others, the assumption of additional liabilities and expenses, difficulties and expenses in connection with integrating the acquired companies and achieving the expected benefits, issuances of potentially dilutive securities or debt, loss of key employees of the acquired companies, transaction costs, diversion of management’s attention from other business concerns and, with respect to the acquisition of non‑U.S. companies, the inability to overcome differences in non‑U.S. business practices, language and customs. Our failure to identify potential acquisitions, complete targeted acquisitions and integrate completed acquisitions or identify and manage strategic alliances or joint ventures could have a material adverse effect on our business, financial condition and results of operations.
 
We have a significant amount of goodwill and intangible assets on our balance sheet, and our results of operations may be adversely affected if we fail to realize the full value of our goodwill and intangible assets.
 
Our balance sheet reflects goodwill and intangibles assets of $1,494.8 million and $704.4 million, respectively, as of December 31, 2018. Collectively, goodwill and intangibles assets represented 69% of our total assets as of December 31, 2018. In accordance with generally accepted accounting principles, or GAAP, goodwill and indefinite-lived intangible assets are not amortized, but are subject to a periodic impairment evaluation. We assess the realizability of our indefinite-lived intangible assets and goodwill annually and conduct an interim evaluation whenever events or changes in circumstances, such as operating losses or a significant decline in earnings associated with the acquired business or asset, indicate that these assets may be impaired. In addition, we review long‑lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. If indicators of impairment are present, we evaluate the carrying value in relation to estimates of future undiscounted cash flows. Our ability to realize the value of the goodwill and intangible assets will depend on the future cash flows of the businesses we have acquired, which in turn depend in part on how well we have integrated these businesses into our own business. The carrying amount of the goodwill could be impaired if there is a downturn in our business or our industry or other factors that affect the fair value of our business, in which case a charge to earnings would become necessary. If we are not able to realize the value of the goodwill and intangible assets, we may be required to incur material charges relating to the impairment of those assets. Such impairment charges could materially and adversely affect our operating results and financial condition. See Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10‑K for a further discussion of our goodwill and intangible asset impairment testing.
 

27

Table of Contents


Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
 
Under Sections 382 and 383 of the U.S. Internal Revenue Code, if a corporation undergoes an “ownership change” (generally defined as a greater than 50 percentage point change, by value, in the aggregate stock ownership of certain stockholders over a three‑year period), the corporation’s ability to use its pre‑change net operating loss carryforwards to offset its future taxable income and other pre‑change tax attributes may be limited. We have experienced at least one ownership change in the past. We may experience additional ownership changes in the future. In addition, future changes in our stock ownership (including future sales by KKR) could result in additional ownership changes. Any such ownership changes could limit our ability to use our net operating loss carryforwards to offset any future taxable income and other tax attributes. State and non‑U.S. tax laws may also impose limitations on our ability to utilize net operating loss carryforwards and other tax attributes.
 
Our business could be harmed if we are unable to manage our growth effectively.
 
We believe that sustained growth places a strain on operational, human and financial resources. To manage our growth, we must continue to improve our operating and administrative systems and to attract and retain qualified management, professional, scientific and technical operating personnel. We believe that maintaining and enhancing both our systems and personnel at reasonable cost are instrumental to our success. We cannot assure you that we will be able to enhance our current technology or obtain new technology that will enable our systems to keep pace with industry developments and the sophisticated needs of our clients. The nature and pace of our growth introduces risks associated with quality control and client dissatisfaction due to delays in performance or other problems. In addition, non‑U.S. operations involve the additional risks of assimilating differences in non‑U.S. business practices, hiring and retaining qualified personnel and overcoming language barriers. Failure to manage growth effectively could have an adverse effect on our business.
 
Our operations involve the use and disposal of hazardous substances and waste which can give rise to liability that could adversely impact our financial condition.
 
We conduct activities that have involved, and may continue to involve, the controlled use of hazardous materials and the creation of hazardous substances, including medical waste and other highly regulated substances. Although we believe that our safety procedures for handling the disposal of such materials generally comply with the standards prescribed by non‑U.S., state and federal laws and regulations, our operations nevertheless pose the risk of accidental contamination or injury caused by the release of these materials and/or the creation of hazardous substances, including medical waste and other highly regulated substances. In the event of such an accident, we could be held liable for damages and cleanup costs which, to the extent not covered by existing insurance or indemnification, could harm our business. In addition, other adverse effects could result from such liability, including reputational damage resulting in the loss of additional business from certain clients.
 
We rely on third parties to provide certain data and other information to us. Our suppliers or providers might increase our cost to obtain, restrict our use of or refuse to license data, which could lead to our inability to access certain data or provide certain services and, as a result, materially and adversely affect our operating results and financial condition.

Our services are derived from, or include, the use of data we collect from third parties. We have several data suppliers that provide us a broad and diverse scope of information that we collect, use in our business and sell.

We generally enter into long-term contractual arrangements with many of our data suppliers. At the time we enter into a new data supply contract or renew an existing contract, suppliers may increase our cost to obtain and use the data provided by such supplier, increase restrictions on our ability to use or sell such data, or altogether refuse to license the data to us. Also, our data suppliers may fail to meet or adhere to our quality control standards or fail to deliver the data to us. Although no single supplier is material to our business, if suppliers that collectively provide a significant amount of the data we receive or use were to increase our costs to obtain or use such data, further restrict our access to or use of such data, fail to meet or adhere to our quality control standards, refuse to provide data or fail to deliver data to us, our ability to provide data-dependent services to our clients may be adversely impacted, which could have a material adverse effect on our business, results of operations, financial condition or cash flow.

We rely on third parties for important products and services, services and licenses to certain technology and intellectual property rights and we might not be able to continue to obtain such products, services and licenses.
 
We depend on certain third parties to provide us with products and services critical to our business. Such services include, among others, suppliers of drugs for patients participating in trials, suppliers of kits for use in our laboratories, suppliers of reagents for use in our testing equipment and providers of maintenance services for our equipment. The failure of

28

Table of Contents


any of these third parties to adequately provide the required products or services, or to do so in compliance with applicable regulatory requirements, could have a material adverse effect on our business.

Some of our services rely on intellectual property, technology and other similar property owned and/or controlled by third parties. Our licenses to this property and technology could terminate or expire and we might not be able to replace these licenses in a timely manner. Also, we might not be able to renew these licenses on similar terms and conditions. Failure to renew these licenses, or renewals of these licenses on less advantageous terms, could have a material adverse effect on our business, results of operations, financial condition or cash flow.
 
We have only a limited ability to protect our intellectual property rights, and these rights are important to our success.
 
Our success depends, in part, upon our ability to develop, use and protect our proprietary methodologies, analytics, systems, technologies and other intellectual property. We rely upon a combination of trade secrets, confidentiality policies, nondisclosure, invention assignment and other contractual arrangements, and copyright, trademark and trade secret laws, to protect our intellectual property rights. Existing laws of the various countries in which we provide services or solutions offer only limited protection of our intellectual property rights, and the protection in some countries may be very limited. The laws of some foreign countries, especially developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Additionally, both in developed and developing countries, these laws are subject to change at any time and certain agreements may not be fully enforceable, which could further restrict our ability to protect our innovations.

Our intellectual property rights may not prevent competitors from independently developing services similar to, or duplicative of, ours. For instance, unauthorized parties may attempt to copy or reverse engineer certain aspects of our products that we consider proprietary or our proprietary information may otherwise become known or may be independently developed by our competitors or other third parties. Further, the steps we take in this regard might not be adequate to prevent or deter infringement or other misappropriation of our intellectual property by competitors, former employees or other third parties, and we might not be able to detect unauthorized use of, or take appropriate and timely steps to enforce, our intellectual property rights. Enforcing our rights might also require considerable time, money and oversight, and we may not be successful in enforcing our rights. It may not be possible to enforce intellectual property rights effectively in some countries at all or to the same extent as in the United States and other countries, and many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.
 
Depending on the circumstances, we might need to grant a specific client greater rights in intellectual property developed in connection with a contract than we otherwise generally do. In certain situations, we might forgo all rights to the use of intellectual property we create, which would limit our ability to reuse that intellectual property for other clients. Any limitation on our ability to provide a service or solution could cause us to lose revenue generating opportunities and require us to incur additional expenses to develop or license new or modified solutions for future projects.
 
Our business has experienced substantial expansion and contraction in the past and we might not properly manage any expansion or contraction in the future.
 
Rapid expansion or contraction, both of which we have experienced, could strain our operational, human and financial resources and facilities. If we fail to properly manage any changes, our expenses might grow more than revenue and our results of operations and financial condition might be negatively affected. In order to manage expansion or contraction, we must, among other things, do the following:
continue to improve our operating, administrative and information systems;
accurately predict our future personnel, resource and facility needs to meet our commitments;
track the progress of ongoing projects; and
attract and retain qualified management, sales, professional, scientific and technical operating personnel. 
In addition, we have numerous business groups, subsidiaries and divisions. If we cannot properly manage these groups, subsidiaries or divisions, it will disrupt our operations. We also face additional risks in expanding our non‑U.S. operations. Specifically, we might find it difficult to:
assimilate differences in non‑U.S. business practices and regulations;
properly integrate systems and operating procedures;
hire and retain qualified personnel; and

29

Table of Contents


overcome language and cultural barriers. 
 
Outsourcing trends in the biopharmaceutical industry and changes in aggregate spending and R&D budgets could adversely affect our operating results and growth rate.
 
We provide services to the biopharmaceutical industry and our revenues depend on the outsourcing trends and R&D expenditures in the industry. Economic factors and industry trends that affect biopharmaceutical companies affect our business. Biopharmaceutical companies continue to seek long‑term strategic collaborations with global CROs with favorable pricing terms. Competition for these collaborations is intense and we may decide to forego an opportunity or we may not be selected, in which case a competitor may enter into the collaboration and our business with the client, if any, may be limited. In addition, if the biopharmaceutical industry reduces its outsourcing of clinical trials or such outsourcing fails to grow at projected rates, our operations and financial condition could be materially and adversely affected. All of these events could adversely affect our business, results of operations or financial condition.
 
Consolidation in the biopharmaceutical industry could lead to a reduction in our revenues.
 
Several large biopharmaceutical companies have completed mergers and acquisitions that will consolidate the outsourcing trends and R&D expenditures into fewer companies. Large pharmaceutical companies represent a significant portion of our customer base. The pharmaceutical industry is currently undergoing a period of increased merger activity. As a result of this and future consolidations, our client diversity may decrease and our business may be adversely affected. In addition, consolidation and other factors in the biopharmaceutical industry, may slow decision making by our clients or result in the delay or cancellation of clinical trials.
 
We may be affected by healthcare reform and potential additional reforms.
 
Numerous government bodies are considering or have adopted various healthcare reforms and may undertake, or are in the process of undertaking, efforts to control growing healthcare costs through legislation, regulation and voluntary agreements with medical care providers and biopharmaceutical companies. We are uncertain as to the effects of these reforms on our business and are unable to predict what legislative proposals, if any, will be adopted in the future. If regulatory cost containment efforts limit the profitability of new drugs, our clients may reduce their R&D spending, which could reduce the business they outsource to us. Similarly, if regulatory requirements are relaxed or simplified drug approval procedures are adopted, the demand for our services could decrease.
 
Government bodies may also adopt healthcare legislation or regulations that are more burdensome than existing regulations. For example, product safety concerns and recommendations by the Drug Safety Oversight Board could change the regulatory environment for drug products, and new or heightened regulatory requirements may increase our expenses or limit our ability to offer some of our services. Additionally, new or heightened regulatory requirements may have a negative impact on the ability of our clients to conduct industry-sponsored clinical trials, which could reduce the need for our services. Furthermore, a relaxation of the scope of regulatory requirements, such as the introduction of simplified marketing applications for pharmaceuticals and biologics, could decrease the business opportunities available to us.
 
Actions by regulatory authorities or clients to limit the scope of or withdraw an approved drug from the market could result in a loss of revenue.
 
Government regulators have the authority, after approving a drug, to limit its indication for use by requiring additional labeled warnings or to withdraw the drug’s approval for its approved indication based on safety concerns. Similarly, clients may act to voluntarily limit the availability of approved drugs or withdraw them from the market after we begin our work. If we are providing services to clients for drugs that are limited or withdrawn, we may be required to narrow the scope of or terminate our services with respect to such drugs, which would prevent us from earning the full amount of service revenue anticipated under the related service contracts.
 
Current and proposed laws and regulations regarding the protection of personal data could result in increased risks of liability or increased cost to us or could limit our service offerings.
 
The confidentiality, collection, use and disclosure of personal data, including clinical trial patient‑specific information, are subject to governmental regulation generally in the country in which the personal data was collected or used. For example, U.S. federal regulations under HIPAA generally require individuals’ written authorization, in addition to any required informed consent, before PHI may be used for research and such regulations specify standards for de‑identifications and for limited data

30

Table of Contents


sets. We may also be subject to applicable state privacy and security laws and regulations in states in which we operate. We are both directly and indirectly affected by the privacy provisions surrounding individual authorizations because many investigators with whom we are involved in clinical trials are directly subject to them as a HIPAA “covered entity” and because we obtain PHI from third parties that are subject to such regulations. Because of amendments to the HIPAA data security and privacy rules, there are some instances where we may be a HIPAA “business associate” of a “covered entity,” meaning that we may be directly liable for any breaches in PHI and other HIPAA violations. These amendments may subject us to HIPAA’s enforcement scheme, which, as amended, can result in up to $1.5 million in annual civil penalties for each HIPAA violation.
 
In the EU and other jurisdictions, personal data includes any information that relates to an identified or identifiable natural person with health information carrying additional obligations, including obtaining the explicit consent from the individual for collection, use or disclosure of the information. In addition, we are subject to laws and regulations with respect to cross‑border transfers of such data out of certain jurisdictions in which we operate, including the EU. If we are unable to transfer data between and among countries and regions in which we operate, it could affect the manner in which we provide our services or adversely affect our financial results. The United States, the EU and its member states, and other countries where we have operations continue to issue new privacy and data protection rules and regulations that relate to personal data and health information. For instance, the EU GDPR, which took effect in 2018, imposes more stringent data protection requirements and will provide for greater penalties for noncompliance. With respect to our operations in Europe, the EU GDPR may increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. Federal, state and non‑U.S. governments may propose or have adopted additional legislation governing the collection, possession, use or dissemination of personal data, such as personal health information, and personal financial data as well as security breach notification rules for loss, theft or unauthorized use of such data that results in significant harm to individuals.

Failure to comply with these data protection and privacy regulations and rules in various jurisdictions, or to resolve any serious privacy or security complaints, could subject us to regulatory sanctions, criminal prosecution or civil liability. Additional legislation or regulation of this type might, among other things, require us to implement new security measures and processes or bring within the legislation or regulation de‑identified health or other personal data, each of which may require substantial expenditures or limit our ability to offer some of our services. Additionally, if we violate applicable laws, regulations or duties relating to the use, privacy or security of personal data, we could be subject to civil liability or criminal prosecution, be forced to alter our business practices and suffer reputational harm.
 
The biopharmaceutical industry has a history of patent and other intellectual property litigation, and we might be involved in costly intellectual property lawsuits.
 
The biopharmaceutical industry has a history of intellectual property litigation, and these lawsuits will likely continue in the future. Accordingly, we may face patent infringement suits by companies that have patents for similar business processes or other suits alleging infringement of their intellectual property rights. Legal proceedings relating to intellectual property could be expensive, take significant time and divert management’s attention from other business concerns, regardless of the outcome of the litigation. If we do not prevail in an infringement lawsuit brought against us, we might have to pay substantial damages, and we could be required to stop the infringing activity or obtain a license to use technology on unfavorable terms.
 
Circumstances beyond our control could cause the CRO industry to suffer reputational or other harm that could result in an industry‑wide reduction in demand for CRO services, which could harm our business.
 
Demand for our services may be affected by perceptions of our clients regarding the CRO industry as a whole. For example, other CROs could engage in conduct that could render our clients less willing to do business with us or any CRO. Although to date no event has occurred causing material industry‑wide reputational harm, one or more CROs could engage in or fail to detect malfeasance, such as inadequately monitoring sites, producing inaccurate databases or analysis, falsifying patient records, and performing incomplete lab work, or take other actions that would reduce the confidence of our clients in the CRO industry. As a result, the willingness of biopharmaceutical companies to outsource R&D services to CROs could diminish and our business could thus be harmed materially by events outside our control.

Our substantial indebtedness could adversely affect our financial condition and prevent us from fulfilling our debt obligations and may otherwise restrict our activities.
 
As of December 31, 2018, we had total indebtedness of $1,086.5 million, which consisted of: $170.0 million principal amount of variable rate accounts receivable financing due in 2021, $916.5 million principal amount of variable rate first lien term loans due in 2021, or the 2016 First Lien Term Loan, and no borrowings under our revolving line of credit, or the 2016

31

Table of Contents


Revolver. The 2016 First Lien Term Loan and 2016 Revolver, which were amended in September 2017 and December 2017, are collectively known as the 2016 Credit Facilities.
 
Specifically, our high level of debt could have important consequences to our business and financial condition, including:
making it more difficult for us to satisfy our obligations with respect to our debt;
limiting our ability to obtain additional financing to fund future working capital, capital expenditures, investments or acquisitions or other general corporate requirements;
requiring a substantial portion of our cash flows to be dedicated to debt service payments instead of other purposes, thereby reducing the amount of cash flow available for working capital, capital expenditures, investments or acquisitions and other general corporate purposes;
increasing our vulnerability to adverse changes in general economic, industry and competitive conditions;
exposing us to the risk of increased interest rates as certain of our borrowings, including borrowings under the 2016 Credit Facilities and accounts receivable financing agreement, are at variable rates of interest;
limiting our flexibility in planning for and reacting to changes in the industry in which we compete;
placing us at a disadvantage compared to other, less leveraged competitors; and
increasing our cost of borrowing.
Despite our level of indebtedness, we may incur more debt and undertake additional obligations. Incurring such debt or undertaking such additional obligations could further exacerbate the risks to our financial condition.
 
Although the credit agreement governing the 2016 Credit Facilities, as amended, contains restrictions on the incurrence of additional indebtedness, these restrictions are subject to a number of qualifications and exceptions, and the indebtedness incurred in compliance with these restrictions could increase. To the extent new debt is added to our current debt levels, the risks to our financial condition would increase.

If we do not comply with the covenants in our financing agreements, we may not have the funds necessary to pay all of our indebtedness that could become due.
 
The credit agreement governing the 2016 Credit Facilities and the accounts receivable financing agreement, as amended, require us to comply with certain covenants. In particular, our credit agreement prohibits us from incurring any additional indebtedness, except in specified circumstances, or amending the terms of agreements relating to certain existing junior indebtedness, if any, in a manner materially adverse to the lenders under our credit agreement without their respective approval. Further, our credit agreement and the accounts receivable financing agreement contain customary covenants, including covenants that restrict our ability to acquire and dispose of assets, engage in mergers or reorganizations, pay dividends or make investments. A violation of any of these covenants could cause an event of default under our financing agreements.

If we default on our financing agreements, all outstanding amounts could become immediately due and payable. If any of the holders of our indebtedness accelerate the repayment of such indebtedness, there can be no assurance that we will have sufficient assets to repay our indebtedness. If we were unable to repay those amounts, the holders of our secured indebtedness could proceed against the collateral granted to them to secure that indebtedness. Any acceleration of amounts due or the substantial exercise by the lenders of their rights under applicable security documents would likely have a material adverse effect on us.
 
We may not be able to generate sufficient cash to service all of our indebtedness, and may be forced to take other actions to satisfy our obligations under our indebtedness that may not be successful.
 
Our ability to satisfy our debt obligations will depend upon, among other things:
our future financial and operating performance, which will be affected by prevailing economic conditions and financial, business, regulatory and other factors, many of which are beyond our control; and
the future availability of borrowings under our 2016 Credit Facilities, which depends on, among other things, our compliance with the covenants in those facilities. 

32

Table of Contents


It cannot be assured that our business will generate sufficient cash flow from operations, or that future borrowings will be available under our 2016 Credit Facilities or otherwise, in an amount sufficient to fund our liquidity needs.
 
If our cash flows and capital resources are insufficient to service our indebtedness, we may be forced to reduce or delay capital expenditures, sell assets, seek additional capital or restructure or refinance our indebtedness. These alternative measures may not be successful and may not permit us to meet our scheduled debt service obligations. Our ability to restructure or refinance our debt will depend on the condition of the capital markets and our financial condition at such time. Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. In addition, the terms of existing or future debt agreements, may restrict us from adopting some of these alternatives. In the absence of such operating results and resources, we could face substantial liquidity problems and might be required to dispose of material assets or operations to meet our debt service and other obligations. We may not be able to consummate those dispositions for fair market value or at all and any proceeds that we could realize from any such dispositions may not be adequate to meet our debt service obligations then due.
 
Interest rate fluctuations may affect our results of operations and financial condition.
 
Because all of our debt is variable‑rate debt, fluctuations in interest rates could have a material effect on our business. We currently utilize derivative financial instruments such as interest rate swaps to hedge our exposure to interest rate fluctuations, but such instruments may not be effective in reducing our exposure to interest fluctuations, and we may discontinue utilizing them at any time. As a result, we may incur higher interest costs if and when interest rates increase. These higher interest costs could have a material adverse impact on our financial condition and the levels of cash we maintain for working capital.

The interest rates of our term loans are priced using a spread over LIBOR.
 
LIBOR, the London Interbank Offered Rate, is the basic rate of interest used in lending between banks on the London interbank market and is widely used as a reference for setting the interest rate on loans globally. We typically use LIBOR as a reference rate in our term loans such that the interest due to our creditors pursuant to a term loan extended to us is calculated using LIBOR. Most of our term loan agreements contain a stated minimum value for LIBOR.

On July 27, 2017, the United Kingdom’s Financial Conduct Authority, which regulates LIBOR, announced that it intends to phase out LIBOR by the end of 2021. It is unclear if at that time whether or not LIBOR will cease to exist or if new methods of calculating LIBOR will be established such that it continues to exist after 2021. The U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, is considering replacing U.S. dollar LIBOR with a new index calculated by short-term repurchase agreements, backed by Treasury securities (“SOFR”). SOFR is observed and backward-looking, which stands in contrast with LIBOR under the current methodology, which is an estimated forward-looking rate and relies, to some degree, on the expert judgment of submitting panel members. Given that SOFR is a secured rate backed by government securities, it will be a rate that does not take into account bank credit risk (as is the case with LIBOR). Whether or not SOFR attains market traction as a LIBOR replacement tool remains in question. As such, the future of LIBOR at this time is uncertain. At this time, due to a lack of consensus existing as to what rate or rates may become accepted alternatives to LIBOR, it is impossible to predict the effect of any such alternatives on our liquidity. However, if LIBOR ceases to exist, we may need to renegotiate our credit agreements that utilize LIBOR as a factor in determining the interest rate to replace LIBOR with the new standard that is established. Additionally, these changes may have an adverse impact on the value of any LIBOR-based marketable securities, loans and derivatives that are included in our financial assets and liabilities.
  
KKR continues to have influence over us, including some control over decisions that require the approval of stockholders, which could limit your ability to influence the outcome of matters submitted to stockholders for a vote.
 
KKR beneficially owned approximately 10.2% of our common stock as of December 31, 2018. Even though KKR does not control a majority of our outstanding voting power, two directors previously nominated by KKR remain on our board of directors and KKR may nominate up to 10% of our board provided it maintains ownership over 5% of our outstanding voting power. As such, KKR has the ability to exercise some control over certain corporate actions that require or may be taken by board approval, including major corporate transactions, changes in the size of our board, the amendment of our bylaws and other changes to corporate governance. Additionally, as a stockholder, KKR may be able to exercise some control over matters requiring stockholder approval, including :
the election and removal of directors and the size of our board of directors;
any amendment of our certificate of incorporation or bylaws; or

33

Table of Contents


the approval of mergers and other significant corporate transactions, including a sale of substantially all of our assets. 

Provisions of our corporate governance documents and Delaware law could make any change in our board of directors or in control of our company more difficult.
 
Our amended and restated certificate of incorporation, our amended and restated bylaws and Delaware law contain provisions, such as provisions authorizing, without a vote of stockholders, the issuance of one or more series of preferred stock, that could make it difficult or expensive for a third party to pursue a tender offer, change in control or takeover attempt that is opposed by our management and board of directors even if such a transaction would be beneficial to our stockholders. We also have a staggered board of directors that could make it more difficult for stockholders to change the composition of our board of directors in any one year. These anti‑takeover provisions could substantially impede the ability of public stockholders to change our management or board of directors.
 
Our operating results and share price may be volatile, which could cause the fair value of our stockholders’ investments to decline.
 
Securities markets worldwide have experienced, and are likely to continue to experience, significant price and volume fluctuations. This market volatility, as well as general economic, market or political conditions, could subject the market price of our shares to wide price fluctuations regardless of our operating performance. Our operating results and the trading price of our shares may fluctuate in response to various factors, including:
market conditions in the broader stock market;
actual or anticipated fluctuations in our quarterly financial and operating results;
introduction of new products or services by us or our competitors;
the public’s reaction to our press releases, our other public announcements and our filings with the SEC;
changes in, or failure to meet, earnings estimates or recommendations by research analysts who track our common stock or the stock of other companies in our industries;
strategic actions by us, our customers or our competitors, such as acquisitions or restructurings;
changes in accounting standards, policies, guidance, interpretations or principles;
issuance of new or changed securities analysts’ reports or recommendations or termination of coverage of our common stock by securities analysts;
sales, or anticipated sales, of large blocks of our stock;
the granting or exercise of employee stock options;
volume of trading in our common stock;
additions or departures of key personnel;
regulatory or political developments;
litigation and governmental investigations;
changing economic conditions;
defaults on our indebtedness; and
exchange rate fluctuations.
These and other factors, many of which are beyond our control, may cause our operating results and the market price and demand for our shares to fluctuate substantially. While we believe that operating results for any particular quarter are not necessarily a meaningful indication of future results, fluctuations in our quarterly operating results could limit or prevent investors from readily selling their shares and may otherwise negatively affect the market price and liquidity of our shares. In addition, in the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a lawsuit could also divert the time and attention of our management from our business, which could significantly harm our profitability and reputation.
 

34

Table of Contents


A significant portion of our total outstanding shares may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.
 
Sales of our common stock into the public market could occur at any time. We have 65,394,526 outstanding shares of common stock as of December 31, 2018. Certain of our stockholders have demand registration rights and “piggyback” registration rights with respect to future registered offerings of our common stock. KKR and other stockholders, who collectively owned 10.2% of our common stock as of December 31, 2018, may sell shares of our common stock. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. We also registered all shares of common stock that we may issue under our equity compensation plans and they can be freely sold in the public market upon issuance, subject to restrictions on transfer contained in management stockholders agreements entered into between certain recipients of equity compensation and KKR and restrictions on sales by our affiliates under Rule 144 under the Securities Act. As restrictions on transfer end, the market price of our stock could decline if the holders of currently restricted shares sell them or are perceived by the market as intending to sell them.
 
Item 1B. Unresolved Staff Comments
 
None.
 
Item 2. Properties
 
We lease a facility for our corporate headquarters in Raleigh, North Carolina. We also lease other offices in North America, Europe, Africa, Latin America, Australia and Asia. In 2018, our total rental expense for our facilities and offices was approximately $39.6 million. We do not own any real estate. We believe that our properties, taken as a whole, are in good operating condition and are suitable for our business operations.
 
Item 3. Legal Proceedings
 
We are currently involved, as we are from time to time, in legal proceedings that arise in the ordinary course of our business. We believe that we have adequately accrued for these liabilities and that there is no other litigation pending that could materially harm our results of operations and financial condition. See "Contingent Liabilities" under Note 2 and Note 13 to our consolidated financial statements included elsewhere in this Annual Report on Form 10‑K for a further discussion of our current legal proceedings.
 
Item 4. Mine Safety Disclosures
 
Not applicable.

35

Table of Contents


PART II
 
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
 
Market Information for Common Stock
 
Our common stock trades on the NASDAQ under the symbol “PRAH.”
 
Holders of Record
 
On February 22, 2019, we had approximately 123 common stockholders of record. This number does not include beneficial owners for whom shares are held by nominees in street name.
 
Recent Sales of Unregistered Securities
 
There were no unregistered sales of equity securities in 2018 that have not been previously reported.
 
Purchases of Equity Securities by the Issuer
 
None.
 
Stock Performance Graph
 
This performance graph shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference into any filing of PRA Health Sciences, Inc.
 
The following graph shows a comparison from November 13, 2014 (the date our common stock commenced trading on the NASDAQ) through December 31, 2018 of the cumulative total return for our common stock, the Nasdaq Composite Index and the Nasdaq Health Care Index.
 
The graph assumes that $100 was invested at the market close on November 13, 2014 in the common stock of PRA Health Sciences, Inc., the Nasdaq Composite Index and the Nasdaq Health Care Index, and assumes reinvestments of dividends, if any. The stock price performance of the following graph is not necessarily indicative of future stock price performance.

36

Table of Contents


shell2018stockperformancegra.jpg

Item 6. Selected Financial Data
 
The following tables set forth, for the periods and at the dates indicated, our selected historical consolidated financial data. We have derived the selected consolidated financial data for the years ended December 31, 2016, 2017 and 2018, and as of December 31, 2017 and 2018, from our audited consolidated financial statements appearing elsewhere in this Annual Report on Form 10‑K. We have derived the selected consolidated financial data for the years ended December 31, 2014 and 2015, and as of December 31, 2014, 2015 and 2016 from our consolidated financial statements not appearing elsewhere in this Annual Report on Form 10‑K. Our historical results are not necessarily indicative of the results we may achieve in any future period.
 
Historical results are not necessarily indicative of the results to be expected in the future.
 
You should read the following information together with the more detailed information contained in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and the accompanying notes appearing elsewhere in this Annual Report on Form 10‑K.


37

Table of Contents


 
Years Ended December 31,
(in thousands, except per share data)
2014
 
2015
 
2016
 
2017
 
2018
Consolidated statement of operations data:
 
 
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
 
 
Service revenue (1)
$
1,266,596

 
$
1,375,847

 
 
 
 
 
 
Reimbursement revenue (1)
192,990

 
238,036

 
 
 
 
 
 
Total revenue (1)
1,459,586

 
1,613,883

 
$
1,811,711

 
$
2,259,389

 
$
2,871,922

Operating expenses:
 
 
 
 
 
 
 
 
 
Direct costs (exclusive of depreciation and amortization)
859,218

 
886,528

 
1,032,688

 
1,283,868

 
1,500,226

Reimbursable out-of-pocket costs
192,990

 
238,036

 
231,688

 
311,015

 
308,291

Reimbursable investigator fees (1)

 

 

 

 
262,114

Selling, general and administrative
253,970

 
246,417

 
269,893

 
321,987

 
371,795

Transaction-related costs

 

 
44,834

 
87,709

 
35,817

Depreciation and amortization
96,564

 
77,952

 
69,506

 
78,227

 
112,247

Loss on disposal of fixed assets
5

 
652

 
753

 
358

 
120

Income from operations
56,839

 
164,298

 
162,349

 
176,225

 
281,312

Interest expense, net
(81,939
)
 
(61,747
)
 
(54,913
)
 
(46,729
)
 
(57,399
)
Loss on modification or extinguishment of debt
(25,036
)
 

 
(38,178
)
 
(15,023
)
 
(952
)
Foreign currency gains (losses), net
10,538

 
14,048

 
24,029

 
(39,622
)
 
(1,043
)
Other (expense) income, net
(2,254
)
 
(1,434
)
 
607

 
(304
)
 
(371
)
(Loss) income before income taxes and equity in (losses) income of unconsolidated joint ventures
(41,852
)
 
115,165

 
93,894

 
74,547

 
221,547

(Benefit from) provision for income taxes
(8,154
)
 
30,004

 
28,494

 
(12,623
)
 
67,232

(Loss) income before equity in (losses) income of unconsolidated joint ventures
(33,698
)
 
85,161

 
65,400

 
87,170

 
154,315

Equity in (losses) income of unconsolidated joint ventures, net of tax
(2,044
)
 
(3,396
)
 
2,775

 
123

 
143

Net (loss) income
(35,742
)
 
81,765

 
68,175

 
87,293

 
154,458

Net income attributable to noncontrolling interest

 

 

 
(366
)
 
(553
)
Net (loss) income attributable to PRA Health Sciences, Inc.
$
(35,742
)
 
$
81,765

 
$
68,175

 
$
86,927

 
$
153,905

Net (loss) income per share:
 
 
 
 
 
 
 
 
 
Basic
$
(0.83
)
 
$
1.36

 
$
1.12

 
$
1.39

 
$
2.40

Diluted
$
(0.83
)
 
$
1.29

 
$
1.06

 
$
1.32

 
$
2.32

Cash dividends declared per common stockholders
$

 
$

 
$

 
$

 
$

Weighted average common shares outstanding:
 
 
 
 
 
 
 
 
 
Basic
42,897

 
59,965

 
60,759

 
62,437

 
64,123

Diluted
42,897

 
63,207

 
64,452

 
65,773

 
66,341

Cash flow data:
 
 
 
 
 
 
 
 
 
Net cash provided by operating activities
$
34,034

 
$
152,428

 
$
160,047

 
$
220,408

 
$
329,792

Net cash used in investing activities
(11,472
)
 
(71,686
)
 
(34,614
)
 
(687,420
)
 
(55,473
)
Net cash (used in) provided by financing activities
(5,956
)
 
(42,444
)
 
(101,595
)
 
507,009

 
(319,512
)
Other financial data:
 
 
 
 
 
 
 
 
 
Backlog (at period end) (2)
$
2,141,112

 
$
2,440,123

 
$
2,934,823

 
$
3,535,611

 
$
4,224,225

Net new business (3)
1,493,652

 
1,696,635

 
2,076,484

 
2,413,730

 
2,644,791

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As of December 31,
 
2014
 
2015
 
2016
 
2017
 
2018
 
 
 
 
 
 
 
 
 
 
Consolidated balance sheet data
 
 
 
 
 
 
 
 
 
Cash and cash equivalents
$
85,192

 
$
121,065

 
$
144,623

 
$
192,229

 
$
144,221

Accounts receivable and unbilled services, net
338,781

 
415,077

 
439,053

 
627,003

 
568,099

Working capital
22,367

 
43,796

 
60,538

 
(94,592
)
 
(116,519
)
Total assets
2,214,484

 
2,228,743

 
2,190,391

 
3,358,046

 
3,186,467

Total long-term debt, net
924,444

 
889,514

 
797,052

 
1,225,397

 
1,082,384

Total liabilities
1,537,669

 
1,526,021

 
1,461,139

 
2,421,565

 
2,135,047

Total stockholders' equity
676,815

 
702,722

 
729,252

 
936,481

 
1,051,420

Total liabilities and stockholders' equity
2,214,484

 
2,228,743

 
2,190,391

 
3,358,046

 
3,186,467


(1)
On January 1, 2018, we adopted Accounting Standards Codification, or ASC, Topic 606, "Revenue from Contracts with Customers," or ASC 606, using the modified retrospective method for all contracts that were not completed as of January 1, 2018. Comparative prior period information continues to be accounted for under the accounting standards in effect for the period presented. The revenue captions for the years ended December 31, 2017 and 2016 have been recast to conform with the presentation of a single revenue total in the consolidated statement of operations as opposed to separate line items. Previously, the year ended December 31, 2017 included service revenue of $1,948.4 million and reimbursement revenue of $311.0 million. The year ended December 31, 2016 included service revenue of $1,580.0 million and reimbursement revenue of $231.7 million.
(2)
Our backlog consists of anticipated service revenue for our Clinical Research segment from new business awards that either have not started or are but have not been completed. Backlog varies from period to period depending upon new business awards and contract increases, cancellations and the amount of service revenue recognized under existing contracts.
(3)
For our Strategic Solutions offering, the value of new business awards is the anticipated service revenue to be recognized in the corresponding quarter of the next fiscal year. For the remainder of our business, net new business is the value of services awarded during the period from projects under signed contracts, letters of intent and, in some cases, pre‑contract commitments that are supported by written communications, adjusted for contracts that were modified or canceled during the period. New business awards are for our Clinical Research segment.


38

Table of Contents


Item 7.  Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
You should read the following discussion and analysis of our financial condition and results of operations together with our “Selected Financial Data” and the consolidated financial statements and the related notes included elsewhere in “Financial Statements and Supplementary Data.” Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, includes forward‑looking statements that involve risks and uncertainties. You should read the “Risk Factors” section of this Annual Report on Form 10‑K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward‑looking statements contained in the following discussion and analysis.
 
Overview
 
We are one of the world’s leading global CROs, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. We believe we are one of a select group of CROs with the expertise and capability to conduct clinical trials across major therapeutic areas on a global basis. Our therapeutic expertise includes areas that are among the largest in pharmaceutical development, and we focus in particular on oncology, immunology, central nervous system inflammation, respiratory, cardiometabolic and infectious diseases. We believe that we further differentiate ourselves from our competitors through our investments in medical informatics and clinical technologies designed to enhance efficiencies, improve study predictability and provide better transparency for our clients throughout their clinical development processes. Our Data Solutions segment allows us to better serve our clients across their entire product lifecycle by (i) improving clinical trial design, recruitment, and execution; (ii) creating real-world data solutions based on the use of medicines by actual patients in normal situations; and (iii) increasing the efficiency of healthcare companies' commercial organizations through enhanced analytics and outsourcing services. 
 
How We Assess the Performance of Our Business
 
We are managed through two reportable segments, (i) Clinical Research and (ii) Data Solutions. Our chief operating decision maker uses segment profit as the primary measure of each segment's operating results in order to allocate resources and in assessing the Company's performance. In addition to our GAAP financial measures, we review various financial and operational metrics. For our Clinical Research segment we review new business awards, cancellations, and backlog.

Our gross new business awards for the years ended December 31, 2018, 2017 and 2016 were $3,023.6 million, $2,779.8 million and $2,367.1 million, respectively. New business awards arise when a client selects us to execute its trial and is documented by written or electronic correspondence or for our Strategic Solutions offering when the amount of revenue expected to be recognized is measurable. The number of new business awards can vary significantly from year to year, and awards can have terms ranging from several months to several years. For our Strategic Solutions offering, the value of a new business award is the anticipated service revenue to be recognized in the corresponding quarter of the next fiscal year. For the remainder of our business, the value of a new award is the anticipated service revenue over the life of the contract, which does not include reimbursement activity or investigator fees.
 
In the normal course of business, we experience contract cancellations, which are reflected as cancellations when the client provides us with written or electronic correspondence that the work should cease. During the years ended December 31, 2018, 2017 and 2016 we had $378.8 million, $366.0 million, and $290.6 million, respectively, of cancellations for which we received correspondence from the client. The number of cancellations can vary significantly from year to year. The value of the cancellation is the remaining amount of unrecognized service revenue, less the estimated effort to transition the work back to the client.
 
Our backlog consists of anticipated service revenue from new business awards that either have not started or are in process but have not been completed. Backlog varies from period to period depending upon new business awards and contract modifications, cancellations, and the amount of service revenue recognized under existing contracts. Our backlog at December 31, 2018, 2017 and 2016 was $4.2 billion, $3.5 billion, and $2.9 billion, respectively.
 
Industry Trends
 
ISR estimated in its 2018 Market Report that the size of the worldwide CRO market was approximately $34 billion in 2017 and will grow at a 7.5% CAGR to $49 billion in 2022. This growth will be driven by an increase in the amount of research and development expenditures and higher levels of clinical development outsourcing by biopharmaceutical companies.
 

39

Table of Contents


Sources of Revenue

Total revenue is comprised of revenue from the provision of our services and revenue from reimbursed expenses, and effective January 1, 2018, also includes reimbursable investigator grants, that are incurred while providing our services. We do not have any material product revenue.

On January 1, 2018, we adopted ASC 606 “Revenue from Contracts with Customers,” using the modified retrospective method for all contracts that were not completed as of January 1, 2018. Thus, in this Item 7 and elsewhere in this report, we report 2018 fiscal year revenue under the modified retrospective method of ASC 606, and continue to report comparative prior period information for the 2017 and 2016 fiscal years under the accounting standards in effect for those periods. See Note 2 to our audited consolidated financial statements found elsewhere in this Annual Report on Form 10-K for additional details regarding our sources of revenue and changes associated with the adoption of ASC 606.

Costs and Expenses
 
Our costs and expenses are comprised primarily of our direct costs, selling, general and administrative costs, depreciation and amortization and income taxes. In addition, we monitor and measure costs as a percentage of revenue, excluding reimbursement revenue from out-of-pocket costs and investigator fees, rather than total revenue, as we believe this is a more meaningful comparison and better reflects the operations of our business. 
 
Direct Costs (Exclusive of Depreciation and Amortization)
 
For our Clinical Research segment, direct costs consist primarily of labor‑related charges. They include elements such as salaries, benefits and incentive compensation for our employees. In addition, we utilize staffing agencies to procure primarily part time individuals to perform work on our contracts. Labor-related charges as a percentage of the Clinical Research segment's total direct costs were 96.0%, 96.4%, and 96.6% for the years ended December 31, 2018, 2017 and 2016, respectively. The cost of labor procured through staffing agencies is included in these percentages and represents 4.5%, 5.6%, and 5.1% of the Clinical Research segment's total direct costs for the years ended December 31, 2018, 2017 and 2016, respectively. Our remaining direct costs are items such as travel, meals, postage and freight, patient costs, medical waste and supplies. The total of all these items as a percentage of the Clinical Research segment's total direct costs were 4.0%, 3.6%, and 3.4% for the year ended December 31, 2018, 2017 and 2016, respectively.

For our Data Solutions segment, direct costs consist primarily of data costs. Data costs as a percentage of the Data Solutions segment's total direct costs were 73.0% and 71.0% for the years ended December 31, 2018 and 2017, respectively. Labor-related charges, such as salaries, benefits and incentive compensation for our employees, were 20.3% and 23.0% of the Data Solutions segment's total direct costs for the years ended December 31, 2018 and 2017, respectively. Our remaining direct costs are items such as travel, meals, and supplies and were 6.7% and 6.0% of the Data Solutions segment's total direct costs for the years ended December 31, 2018 and 2017, respectively.

Historically, direct costs have increased with an increase in revenues. The future relationship between direct costs and revenue may vary from historical relationships. Excluding the adoption of ASC 606, direct costs as a percentage of revenue were 65.3%, 65.9%, and 65.4% during the years ended December 31, 2018, 2017, and 2016, respectively. Several factors will cause direct costs to decrease as a percentage of revenue. Deployment of our billable staff in an optimally efficient manner has the greatest impact on our ratio of direct cost to revenue. The most effective deployment of our staff is when they are fully engaged in billable work and are accomplishing contract related activities at a rate that meets or exceeds budgeted targets. We also seek to optimize our efficiency by performing work using the employee with the lowest cost. Generally, the following factors may cause direct costs to increase as a percentage of revenue: our staff are not fully deployed, as is the case when there are unforeseen cancellations or delays, or when our staff are accomplishing tasks at levels of effort that exceed budget, such as rework; as well as pricing pressure from increased competition.

Reimbursable Out-of-Pocket Costs and Reimbursable Investigator Fees 

We incur out-of-pocket costs that are reimbursable by our customers. As is customary in our industry, we also routinely enter into separate agreements on behalf of our clients with independent physician investigators in connection with clinical trials. We do not pay independent physician investigators until funds are received from the applicable clients. We include these out-of-pocket costs as reimbursable out-of-pocket expenses and these investigator fees as reimbursable investigator fees in our consolidated condensed statements of operations. Reimbursable costs and investigator fees are not included in our backlog because they are pass-through costs to our clients. 


40

Table of Contents


We believe that the fluctuations in reimbursement costs and the associated revenue are not meaningful to our economic performance given that such costs are passed through to the client. The reimbursable costs are included in our measure of progress for our long-term contracts.

Selling, General and Administrative Expenses
 
Selling, general and administrative expenses consist of administration payroll and benefits, marketing expenditures, and overhead costs such as information technology and facilities costs. These expenses also include central overhead costs that are not directly attributable to our operating business and include certain costs related to insurance, professional fees and property.

Transaction-Related Costs
 
Transaction-related costs consist of expenses incurred with our secondary offerings, transaction-related stock-based compensation awards, revaluations of contingent consideration related to business combinations and other transaction costs, the closing of our accounts receivable financing agreement and the subsequent amendment to the agreement, fees associated with the Incremental Borrowing (defined below), and our refinancing of the 2013 Credit Facilities (defined below).
 
Loss on Modification or Extinguishment of Debt
 
The loss on modification or extinguishment of debt during the year ended December 31, 2018 is related to previously capitalized unamortized debt financing costs that were expensed as a result of voluntary debt repayments made during the year. Loss on modification or extinguishment of debt for the year ended December 31, 2017 was associated with the September 2017 incremental borrowing under the 2016 Credit Facilities, or the Incremental Borrowing, redemption of our 9.5% senior notes due 2023, or Senior Notes, and the December 2017 amendment to the 2016 Credit Facilities, or the 2017 Refinancing. Loss on extinguishment of debt for the year ended December 31, 2016 was associated with our cash tender offer on Senior Notes and the refinancing of our variable rate first lien term loan due 2020, or 2013 First Lien Term Loan, and revolving line of credit, or 2013 Revolver, collectively known as the 2013 Credit Facilities.

Depreciation and Amortization
 
Depreciation represents the depreciation charged on our fixed assets. The charge is recorded on a straight‑line method, based on estimated useful lives of three to seven years for computer hardware and software and five to seven years for furniture and equipment. Leasehold improvements are depreciated over the lesser of the life of the lease term or the useful life of the improvements. Amortization expense consists of amortization recorded on acquisition‑related intangible assets. Customer relationships, backlog, databases and finite‑lived trade names are amortized on an accelerated basis, which coincides with the period of economic benefit we expect to receive. All other finite‑lived intangibles are amortized on a straight‑line basis. In accordance with GAAP, we do not amortize goodwill and indefinite‑lived intangible assets.
 
Income Taxes
 
Because we conduct operations on a global basis, our effective tax rate has and will continue to depend upon the geographic distribution of our pre‑tax earnings among several different taxing jurisdictions. Our effective tax rate can also vary based on changes in the tax rates of the different jurisdictions. Our effective tax rate is also impacted by tax credits and the establishment or release of deferred tax asset valuation allowances and tax reserves, as well as significant non‑deductible items such as portions of transaction‑related costs.
 
Foreign subsidiaries are taxed separately in their respective jurisdictions. We have foreign net operating loss carryforwards in some jurisdictions. The carryforward periods for these losses vary from four years to an indefinite carryforward period depending on the jurisdiction. Our ability to offset future taxable income with the net operating loss carryforwards may be limited in certain instances, including changes in ownership.

Business Combinations
 
We have completed and will continue to consider strategic business combinations to enhance our capabilities and offerings in certain areas. In September 2017, we acquired Symphony Health, which has enhanced our ability to serve customers throughout the clinical research process with technologies that provide data and analytics. Additionally, in May 2017, we acquired Parallel 6, Inc., or Parallel 6, which has allowed us to offer our customers technologies that provide improved efficiencies by reducing study durations and costs through integrated operational management.

41

Table of Contents


 
These transactions were accounted for as business combinations and the acquired results of operations are included in our consolidated financial information since the acquisition date.

See Note 4 to our audited consolidated financial statements found elsewhere in this Annual Report on Form 10-K for additional information with respect to these and other smaller acquisitions.
 
Joint Ventures
 
In June 2017, we closed on a joint venture transaction with Takeda Pharmaceutical Company Ltd., or Takeda, that enables us to provide clinical trial delivery and pharmacovigilance services as a strategic partner of Takeda Japan. The joint venture was effectuated through the creation of a new legal entity, Takeda PRA Development Center KK, or TDC joint venture. The TDC joint venture is based in Japan and is owned by us (50%) and Takeda (50%).

See Note 3 and Note 4 to our audited consolidated financial statements found elsewhere in this Annual Report on Form 10-K for additional information with respect to the joint ventures.
 
Exchange Rate Fluctuations
 
The majority of our foreign operations transact in the Euro, or EUR, or British pound, or GBP. As a result, our revenue and expenses are subject to exchange rate fluctuations with respect to these currencies. We have translated these currencies into U.S. dollars using the following average exchange rates:
 
 
Years Ended December 31,
 
2018
 
2017
 
2016
U.S. dollars per:
 
 
 
 
 
Euro
1.18

 
1.13

 
1.11

British pound
1.33

 
1.29

 
1.35



42

Table of Contents


Results of Operations
 
Consolidated Results of Operations for the Year Ended December 31, 2018 Compared to the Year Ended December 31, 2017
 
 
 
 
 
Change
 
 
 
 
Year Ended December 31, 2017
 
$ Change
 
Adoption of ASC 606 (1)
 
Year Ended December 31, 2018
(in thousands)
 
 
 
 
 
 
 
 
Revenue
 
 
 
 
 
 
 
 
Service revenue
 
$
1,948,374

 
$
348,475

 
$

 
 
Reimbursement revenue - out-of-pocket costs
 
311,015

 
(2,724
)
 

 
 
Total revenue
 
2,259,389

 
345,751

 
266,782

 
$
2,871,922

Operating expenses
 
 
 
 
 
 
 
 
Direct costs (exclusive of depreciation and amortization)
 
1,283,868

 
216,358

 

 
1,500,226

Reimbursable out-of-pocket costs
 
311,015

 
(2,724
)
 

 
308,291

Reimbursable investigator fees
 

 

 
262,114

 
262,114

Selling, general and administrative
 
321,987

 
49,808

 

 
371,795

Transaction-related costs
 
87,709

 
(51,892
)
 

 
35,817

Depreciation and amortization
 
78,227

 
34,020

 

 
112,247

Loss on disposal of fixed assets
 
358

 
(238
)
 

 
120

Income from operations
 
176,225